Clinical trial NCT03482440
Conditions: Preeclampsia
Keywords: preeclampsia microvascular inflammation angiotensin II
Sponsor: University of Iowa
Start date: 2018-08-26; Completion date: 2022-12-31
Enrollment: 24 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
Women who develop preeclampsia during pregnancy are more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to 1) determine the mechanisms contributing to this lasting blood vessel damage and chronic inflammation, and to 2) identify factors (both physiological and pharmacological) that mitigate these negative effects in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

Detailed description:

Arms: arm 1: None arm 2: None
Interventions: intervention 1: Salsalate Oral Tablet intervention 2: Placebo Oral Tablet
Intervention descriptions: intervention 1: 1500mg twice daily for 4 days prior to experimental testing intervention 2: Placebo oral table twice daily for 4 days prior to experimental testing

Protocol documents:
Prot_SAP_000.pdf: 
College of Liberal Arts  
and Sciences 
Department of Health and Human 
Physiology 
University of Iowa 
E102 Field House 
Iowa City, Iowa 52242-1111 
319-384-4664   Fax 319-335-6669 
 
 
 
 
 
 
Document date: July 14, 2020 
 
Project title: Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction 
Following Preeclampsia 
 
NCT #: 03482440 


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
ang II and inflammation following preeclampsia
PI:
Anna Reid-Stanhewicz
IRB ID #: 201909818
Project Details
I. Project Introduction
I.1
Project to be reviewed by:
IRB-01
I.2
Project Title:
Role of angiotensin II and inflammation in persistent vessel dysfunction following preeclampsia
I.3
Short Title (optional):
ang II and inflammation following preeclampsia
I.4
Provide a short summary of the purpose and procedures of the study proposed in this IRB application.
DO NOT include information on studies not proposed in this application.
Use LAY terminology only. This must be easily understandable by IRB community members and
nonscientists.
DO NOT cut and paste technical abstracts from funding applications that may not be understood by a general
audience.
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life,
even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and
increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this
investigation is to determine the mechanisms contributing to this lasting blood vessel damage and chronic inflammation, and to
identify factors that may decrease these negative effects in women who have had preeclampsia. Identification of these
mechanisms may lead to better clinical management of cardiovascular disease risk in these women. 
In this study we use the blood vessels in the skin as a representative vascular bed. Using a minimally invasive technique
(intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickle-sized area
of the skin and compare the responses of the blood vessels in women who have had preeclampsia to those of our control
group, women who have had an uncomplicated pregnancy. We make these measurements after the subjects take a placebo
and after they take an anti-inflammatory medication (salsalate) to test the role of inflammation in the differences we see
between groups. As a compliment to these measurements, we also draw blood from the subjects and isolate the inflammatory
cells to test how sensitive their inflammatory responses are.
I.5
Specify your research question(s), study aims or hypotheses (do not indicate "see protocol")
Specific Aim: To define the mechanistic role of Angiotensin II (Ang II) signaling in microvascular inflammation and associated
endothelial dysfunction in women who have had preeclampsia (PreEC) compared to control women who have had a healthy
pregnancy (HC). 
Using intradermal microdialysis for the in vivo assessment of microvascular signaling mechanisms, we will test the hypotheses
that PreEC have (1) increased constrictor sensitivity to Ang II and (2) reduced endothelium-dependent vasodilation, both of
which will be normalized post-systemic inhibition of inflammation. We will also utilize peripheral blood mononuclear cells
(PBMC) collected pre and post-salsalate treatment to test the hypothesis that (3) immune cells from PreEC have a greater
inflammatory response to stimulation with Ang II. 
NOTE: This IRB protocol encompasses the projects of aim 1 in the attached NIH K99/R00 award. Aim 2 has been completed
and aim 3 will be included in a separate IRB application to come later. 
I.6
Background and significance and/or Preliminary studies related to this project.
(do not indicate "see protocol")
Angiotensin II Sensitivity Contributes to Endothelial Dysfunction Following Preeclampsia: Women with a history of preeclampsia
have an exaggerated presser response to systemic infusion of Ang II. Similarly, compelling in vivo pilot data from our lab
demonstrates that this increased sensitivity to Ang II is present in the microcirculation and contributes to endothelial
dysfunction postpartum in formerly preeclamptic patients. Ang II mediates several events of the inflammatory process
including activation of the vascular endothelium; and AT1R activation plays a large role in the pathophysiology of concurrent
inflammatory reactions through this direct action on local vascular cells. Inhibition of Ang II, either through ACE inhibition or
AT1-receptor antagonism, reduces tissues inflammation and oxidative injury. Reciprocally, inhibition of inflammatory mediators
such as IL-17 producing T cells blunts the pressor response to systemic Ang II infusion in animal models of hypertension.
Collectively, increased sensitivity to Ang II coupled with the role of Ang II signaling in chronic inflammation, suggests that
these factors are likely reciprocal, and contribute to microvascular dysfunction and elevated CVD risk in women who have had
preeclampsia. 
Interestingly, women who have had preeclampsia do not have elevated circulating Ang II. However, evidence suggests that
activating AT1R autoantibodies (AT1-AAs) develop in women during a preeclamptic pregnancy and remain elevated post-
partum. AT1-AAs contribute to the vascular pathology of preeclampsia in animal models, and isolated AT1-AAs induce a dose-
dependent vasoconstriction response and the upregulation of pro-inflammatory cytokines. Importantly, these responses are
mediated through AT1R binding at the cell membrane, and are inhibited by AT1R blockade. Chronically elevated AT1-AAs post-
partum likely contribute to persistent inflammation and endothelial dysfunction in women who have had preeclampsia,
independent of endogenous Ang II concentrations. As such, this unique mechanism highlights the relevance of the
inflammatory pathway and AT1R sensitivity, as well as the therapeutic potential of physiological (Ang 1-7) and pharmacological
(salsalate) inhibitors of AT1R signaling and/or inflammation, in the vascular dysfunction that persists post-partum in women


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
who have had preeclampsia. 
Angiotensin 1-7 is an Endogenous Inhibitor of Ang II: Angiotensin 1-7 (Ang 1-7), a protective component of the renin-
angiotensin system, acts on its receptor, mas, to oppose the intracellular actions of Ang II-AT1R signaling. Ang 1-7 – mas
receptor binding produces vasodilation, inhibits cell growth, and has anti-inflammatory15, 16 and anti-thrombotic effects.
Plasma Ang 1-7 concentrations increase during healthy pregnancy, but are significantly decreased in preeclampsia. There is a
negative correlation between plasma Ang 1-7 and both systolic and diastolic blood pressure in preeclampsia19, however few, if
any, mechanistic studies examining this relation have been performed in humans. Similarly, to date, there have been no
human studies of Ang 1-7 in postpartum women who have had preeclampsia. As an endogenous inhibitor of the intracellular
actions of AT1R signaling, Ang 1-7 has emerged as a novel protective pathway in conditions of endothelial dysfunction,
including diabetes and essential hypertension. Given the role of increased AT1R signaling – through increased Ang II sensitivity
and elevated plasma AT1-AA – in persistent vascular dysfunction post-partum, the actions of Ang 1-7 may be a currently
unexplored mechanistic target for the attenuation of inflammation and endothelial dysfunction in women who have had
preeclampsia. 
The overarching theme of this project – aberrant Ang II signaling and chronic inflammation in the microvasculature of women
who have had preeclampsia – is innovative in its delineation of novel mechanisms and interventional targets in an in vivo
human microvascular bed. The proposed series of studies utilize state-of-the-art techniques to pharmaco-dissect the
deleterious role of Ang II signaling as well as the potentially protective role of Ang 1-7 signaling, in chronic inflammation and
endothelial dysfunction in vivo in the human cutaneous microvasculature. Coupled with innovative in vitro measures of immune
cell activity and acute systemic inhibition of inflammation, these studies will provide new insight into novel mechanistic targets
for intervention. 
I.7
Literature cited / references (if attaching a grant or protocol enter N/A).
N/A
II. Research Team
II.1
Principal Investigator
Name
E-mail
College
Anna Reid-Stanhewicz anna-stanhewicz@uiowa.edu College Lib Arts and Sciences
II.2
Team Members
UI Team Members
Name
E-mail
College
Contact Key
Prsn
UI
COI
VAMC
COI
Consent
Process
Involvement
Deactivated
Anna Reid-Stanhewicz, PHD anna-
stanhewicz@uiowa.edu
College Lib
Arts and
Sciences
Yes
Yes
No
Yes
No
Kaila Brustkern, BS
kaila-
brustkern@uiowa.edu
College Lib
Arts and
Sciences
No
No
No
Yes
No
Diana Jalal, MD
diana-jalal@uiowa.edu
Carver
College of
Medicine
No
Yes
No
No
No
Michael Pyevich, AA
michael-
pyevich@uiowa.edu
College of
Liberal Arts
and
Sciences
No
No
No
No
No
Non-UI Team Members
Name Institution Location FWA Role DHHS Contact
Key
Prsn
UI
COI
VAMC
COI
Consent Process
Involvement
Email
Nothing found to display.
II.3
The Principal Investigator of this study is:
Faculty
II.6
Identify the key personnel. The system will automatically designate the PI and all faculty members on the project as
“key personnel.” For information about other team members who should be designated as “key personnel” please click
on the help information.
Name
Is Key Personnel
Anna Reid-Stanhewicz, PHD
Yes
Kaila Brustkern, BS
No
Diana Jalal, MD
Yes
Michael Pyevich, AA
No
II.5
Select research team member who is the primary contact for study participants.
Anna Reid-Stanhewicz


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
III. Funding/Other Support
III.1
Funding Sources
Type
Source
Grant Title Name of PI on Grant
Federal Agency US Department of Health & Human Services, National Institutes of Health
Role of
Angiotensin II
and Chronic
Inflammation
in Persistent
Microvascular
Dysfunction
Following
Preeclamptic
Pregnancy
Anna Stanhewicz
* new source name
III.2
What type of funding agreement would be completed?
Federal/State/Local Agency/Non-Profit Funded/Other
III.3
Does any member of the research team have a financial conflict of interest related to this project according to the
Conflict of Interest in Research policy? If yes, please indicate which members below.
Name
Has Conflict of Interest
Anna Reid-Stanhewicz, PHD
No
Kaila Brustkern, BS
No
Diana Jalal, MD
No
Michael Pyevich, AA
No
III.5
What is the current status of this funding source?
Source
Status Other Status Description
US Department of Health & Human Services, National Institutes of Health Awarded
IV. Project Type
IV.1
Do you want the IRB to give this project
Regular (expedited or full board) review
IV.2
Enter the date you will be ready to begin screening subjects/collecting data for this project. (If you do not have a
specified date, add "upon IRB approval")
upon IRB approval
IV.3
Are you requesting a waiver of informed consent/authorization (subjects will not be given any oral or written
information about the study)?
No
V. Other Committee Review
V.1
Does this project involve any substance ingested, injected, or applied to the body? 
Do not answer yes, if the involvement includes a device, wire, or instrument
Yes
V.1.a
What is/are the substance(s):
Note: All of the following research agents used with microdialysis have been approved by the FDA for this study under IND#
124,294.
Acetylcholine, Powder
Angiotensin II, Powder
NG-nitro-L-arginine methyl ester, Powder
Sodium Nitroprusside, Powder
Lactated Ringer’s, Liquid
Salsalate, Tablet
Placebo, Tablet
V.1.b
Are any of these substances defined as a Schedule I - V Controlled Substance?
No
V.2
Are any contrast agents used for any purpose in this study?
No
V.4
Are all drugs or substances in this study being used within the FDA approved population (i.e., children, adults)?
Yes


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
V.5
Are all drugs or substances in this study being used within the FDA approved indication (i.e., disease, condition)?
No
V.6
Are all drugs or substances in this study being used within the FDA approved dose?
No
V.7
Are all drugs or substances in this study being used within the FDA approved route of administration?
No
V.8
Drugs used in study that are not FDA approved for the population, indication, dose, or route of
administration
Salsalate
()
Name of Sponsor
Anna Stanhewicz
Investigator's Brochure Version
N/A
Investigator's Brochure Date
N/A
Who is supplying the drug
Who is dispensing the drug
IND#
124,294
Dose
3000mg/day for 5 days
Route of administration
oral
acetylcholine
()
Name of Sponsor
Anna Stanhewicz
Investigator's Brochure Version
N/A
Investigator's Brochure Date
N/A
Who is supplying the drug
Who is dispensing the drug
IND#
124,294
Dose
<0.01mg
Route of administration
intradermal microdialysis
NG-nitro-L-arginine methyl ester (L-NAME)
()
Name of Sponsor
Anna Stanhewicz
Investigator's Brochure Version
N/A
Investigator's Brochure Date
N/A
Who is supplying the drug
Who is dispensing the drug
IND#
124,294
Dose
<0.01mg
Route of administration
intradermal microdialysis
angiotensin II
()
Name of Sponsor
Anna Stanhewicz
Investigator's Brochure Version
N/A
Investigator's Brochure Date
N/A
Who is supplying the drug
Who is dispensing the drug
IND#
124,294
Dose
<0.01mg
Route of administration
intradermal microdialysis
sodium nitroprusside (SNP)
()
Name of Sponsor
Anna Stanhewicz
Investigator's Brochure Version
N/A
Investigator's Brochure Date
N/A
Who is supplying the drug
Who is dispensing the drug
IND#
124,294
Dose
<0.01mg
Route of administration
intradermal microdialysis
lactated Ringer's
()
Name of Sponsor
Anna Stanhewicz
Investigator's Brochure Version
N/A
Investigator's Brochure Date
N/A
Who is supplying the drug
Who is dispensing the drug
IND#
124,294
Dose
N/A
Route of administration
intradermal microdialysis


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
V.9
Will any subject be asked to undergo a diagnostic radiation procedure (including radiographic, nuclear medicine,
DEXA)?
No
V.14
Will any subject be asked to undergo a radiation therapy procedure (including external beam therapy, brachytherapy,
or nuclear medicine therapy)?
No
V.20
Does this project involve the deliberate transfer of recombinant or synthetic nucleic acid molecules, or DNA or RNA
derived from recombinant or synthetic nucleic acid molecules, into one or more human research participant?
No
V.21
Will any portion of this project be conducted in the CRU, or does it use any CRU resources?
Yes
V.22
Will this project use: 
any resource/patients of the Holden Comprehensive Cancer Center
involve treatment, detection, supportive care, or prevention of cancer
No
V.25.a
Will the study involve any of the following activity at UI Health Care, even if subjects or their insurance will not be
billed for the item or service, and regardless of the study funding source (including studies with departmental or no
funding)?
Procedures, tests, examinations, hospitalizations, use of Pathology services, use of clinic facilities or clinical
equipment, or any patient care services, including services conducted in the Clinical Research Unit; or
Physician services or services provided by non-physicians who are credentialed to bill (ARNPs, Physician
Assistants, etc.)
Yes
V.25.b
Will there be any procedures or services that may happen as part of a subject’s regular medical care and as
part of the study?
No
V.25.c
Will any study equipment or devices be supplied by a study sponsor?
No
V.25.e
Is there or will there be an internal budget for this study?
No
V.25.f
Is there or will there be an external budget for this study?
Yes
V.26
The study involves Department of Nursing Services and Patient Care nursing, nursing resources or evaluates
nursing practices at UI Health Care.
No
VI. Subjects
VI.1
How many adult subjects do you expect to consent or enroll for this project?
40
VI.2
What is the age of the youngest adult subject?
18.0
VI.3
What is the age of the oldest adult subject?
100.0
VI.4
What is the percentage of adult male subjects?
0
VI.5
What is the percentage of adult female subjects?
100
VI.6
How many minor subjects do you expect to consent or enroll for this project?
0
VI.13
Describe EACH of your subject populations
Include description of any control group(s)
Specify the Inclusion/Exclusion criteria for EACH group


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
INCLUSION CRITERIA: Post-partum women who have delivered within two years and who have had a preeclamptic pregnancy
diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for
preeclampsia. [This information will be self-reported by the subjects.] Women without a history of preeclampsia matched for age,
parity, and time post-partum. 18 years old and older. 
EXCLUSION CRITERIA: We exclude participants for skin diseases, current tobacco use, diagnosed or suspected hepatic or metabolic
disease, statin or other cholesterol-lowering medication, history of hypertension prior to pregnancy, history of gestational diabetes,
current pregnancy, body mass index <18.5 kg/m2, allergy to aspirin or NSAIDs, or known allergy to materials used during the
experiment.(e.g. latex). We exclude for renal disease, bleeding disorders and history of gastrointestinal bleeding. Known allergies to
study drugs. Taking blood thinners, aspirin or NSAIDS. Women who choose to breastfeed will not participate.
VI.14
Provide an estimate of the total number of subjects that would be eligible for inclusion in each of your study
populations (include your control population if applicable)
We will recruit subjects from Johnson and surrounding counties in Iowa. According to the Iowa Department of Public Health, Johnson
county has a live birth rate of 11.7/1,000 residents or ~1,750 live births per year. Surrounding counties range from 9.6-12 live
births/1,000, adding ~4,000 additional live births annually within the geographical area of reach. Assuming an average rate of 7%
for preeclampsia incidence, approximately 400 women would be eligible to participate in the preeclamptic group each year. We will
recruit women within 2 years postpartum so we estimate that there are approximately 800 eligible participants in our geographic
area at any given time. Approximately 2,900 women will be eligible to participate in the control group.
VI.15
Describe how you will have access to each of your study populations in sufficient number to meet your recruitment
goals.
We will advertise for participants by posting fliers in the community and in clinicians offices where permission has been granted(see
attached flier). We will also post this flier in digital spaces such as on facebook and twitter. Participants will be recruited from the
University of Iowa and Iowa City, Iowa by mass email (see attached mass email text) and the Noon News (see attached Noon news
posting) a newsletter available on campus at UIHC. All individuals interested in participating will be directed to contact research staff
by phone or email. All individuals interested in the study will be invited to complete the RedCap eligibility survey sent via email. If an
individual appears to be eligible for the study based on their RedCap Eligibility survey responses, a member of the research team will
contact them via phone or email to tell the individual more about the study, answer any questions, and perform a phone screening to
determine eligibility.
VI.16
Do you plan to recruit/enroll non-English speaking people?
No
VI.18
Do you propose to enroll any of the following in this study as subjects?
Employee of the PI or employee of a research team member
Individual supervised by PI or supervised by member of research team
Individual subordinate to the PI or subordinate to any member of the research team
Student or trainee under the direction of the PI or under the direction of a member of the research team
No
VI.20
Will subjects provide any information about their relatives?
No
VI.23
Will anyone (other than the subject) provide you with information about the subject (e.g. proxy interviews)?
No
VI.26
Is this project about pregnant women?
No
VI.27
Will this project involve fetuses?
No
VI.28
Does this project involve adult subjects who may be incompetent or have limited decision-making capacity on initial
enrollment into the study?
No
VI.32
Does this project involve subjects whose capacity to consent may change over the course of the study?
No
VI.37
Does this project involve prisoners as subjects?
No
VII.A. Project Description (A)
VII.A.1
Where will project procedures take place (check all that apply)?
Other UI campus site
- 528 Field House
CRU
VII.A.2
Is this project also being conducted by other researchers at their own sites (e.g. a multi-site collaborative project)?
No


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
VII.B. Project Description (B)
VII.B.1
Does this project involve any of the following (Check all that apply):
VII.B.1.b
Provide the NCT (National ClinicalTrials.gov Identifier) number
NCT03482440
VII.B.2
Does this project involve a drug washout (asking subject to stop taking any drugs s/he is currently taking)?
No
VII.B.11
Is there a separate, written protocol that will be submitted in addition to this IRB New Project form? (Note: a grant
application is not considered to be a protocol)
No
VII.B.18
Does this project involve testing the safety and/or efficacy of a medical device?
No
VII.C. Project Description (C)
VII.C.1
Does this project involve any research on genes or genetic testing/research?
No
VII.D. Project Description (D)
VII.D.1
Check all materials/methods that will be used in recruiting subjects (you will need to attach copies of all materials at
the end of the application):
Website
- https://clinicaltrials.gov/ct2/show/NCT03482440?recrs=ab&cond=Preeclampsia&cntry=US&state=US%3AIA&rank=1
Advertisements
-
Posters
-
E-mail
-
VII.D.8
Will a member of the research team discuss the study with the subject in person prior to the subject agreeing to
participate?
Yes
VII.D.9
Describe the physical location where the consent process will take place:
The research staff will discuss the study with potential subjects in a conference room or exam room in the ICTS clinical
research unit.
VII.D.10
Will a member of the research team discuss the study with the subject by phone prior to the subject agreeing to
participate?
Yes
VII.D.11
Describe:
Registry – The collection and maintenance of data (not including biologic samples) in which: (1) the individuals in the
registry have a common or related condition(s), and/or (2) the individuals in the registry are interested in being contacted
for future studies by investigators other than those listed in Section II of this project.(UI Guide)
Repository – The collection, storage, and distribution of human biologic samples and/or data materials for research
purposes. Repository activities involve three components: (i) the collection of data and/or specimens such as blood, tissue,
saliva, etc.; (ii) the storage of data or specimens, and data management function; and (iii) the sharing of data/specimens
with recipient investigators other than the original investigators. (paraphrased from OHRP)
Expanded Access – A process regulated by the Food and Drug Administration (FDA) that allows manufacturers to provide
investigational new drugs to patients with serious diseases or conditions who cannot participate in a clinical trial. Examples
of expanded access include non-protocol access to experimental treatments, including protocol exception, single-patient
IND, treatment IND, compassionate use, emergency use, continued access to investigational drug, and parallel track
(ClinicalTrials.gov & FDA).
Clinical (or Treatment) trial – A prospective biomedical or behavioral research study of new treatments, new drug or
combinations of drugs, new devices, or new approaches to surgery or radiation therapy. (NIH and ClinicalTrials.gov & FDA)
Physiology intervention/study – A pharmacologic or measurement study aimed at understanding basic mechanisms of
disease and/or of normal human physiology, often without any therapeutic intent (though a clinical trial could include such
components, often labeled as “translational” or “basic science” aims.) Measurements in such studies could include, but are
not limited to, a blood draw, EKG, EEG, MRI, auditory or sensory testing, checking vital signs, DEXA scans, eye tracking,
specimen collection, exercise, fasting, special diets, etc.
Behavioral intervention/study – May be used to refer to studies of individual or group behavior. This option does not
include drugs, biologics, or devices but could include psychotherapy, lifestyle counseling, behavior modification, etc.
Diagnostic trial – Protocol designed to evaluate one or more interventions aimed at identifying a disease or health
condition (ClinicalTrials.gov & FDA)
Non-clinical – any college/department that would regularly submit to IRB-02
Other


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
Research staff will discuss the project over the phone with individuals who are interested in participating in the study. (see pre-
consent phone script) This will take place in the research office in 528FH. During the call, the research team member will
answer any questions and describe the study to the individual as needed. If the subject is still interested in participating they
will be given access to the RedCap pre-consent screening survey. If the individual continues to meet eligibility after completing
this survey, they will be given information about the study, but will not be consented over the phone. If the subject agrees,
they will come to clinical research. and be consented and proceed with Visit 1.
VII.D.12
Who will be involved in the consent process (including review of consent document, answering subjects'
questions)?
Name
Consent Process Involvement
Anna Reid-Stanhewicz, PHD
Yes
Kaila Brustkern, BS
Yes
Diana Jalal, MD
No
Michael Pyevich, AA
No
VII.D.15
Check all materials that will be used to obtain/document informed consent:
Consent Document
VII.D.16
Are you requesting a waiver of documentation of consent (either no subject signature or no written document)?
No
VII.D.19
Before the subject gives consent to participate are there any screening questions that you need to directly ask the
potential subject to determine eligibility for the study?
Yes
VII.D.20
List any screening questions you will directly ask the potential subject to determine eligibility.
Eligibility Survey: (see attached pre-consent online survey) This survey will be administered via REDCap link delivered by
email. Participants will be invited to complete a survey to determine their eligibility. Age, height, weight and months since they
delivered will be collected so that subjects with a history of preeclampsia may be matched with controls. 
If subjects' responses to the online screening survey deem them eligible, they will be contacted by a member of the research
team via phone to complete an additional screening (see RedCap attachment Additional Info Survey). Some questions are
duplicates to the aforementioned online questionnaire and will be asked again to confirm the absence of major exclusion
criteria.
VII.D.21
Will you keep a screening log or other record that would include information on people who do not enroll in the
study?
Yes
VII.D.22
Describe the information being collected and the purpose for keeping this information.
The following information will be collected in a screening log: 
1. Subject's name 
2. Age 
3. How they heard about study 
4. Date that they contacted the study 
5. How they contacted us (phone/email) 
6. Date of phone screening 
7. Phone number 
8. Email address 
9. Pass online screening; yes or no 
10. If did not pass online screening, reason? 
11. Pass phone screen? Yes or No 
12. If did not pass phone screen, reason? 
13. If passed phone screening, date of consent 
14. Signed informed consent 
Contact information is required to contact the subjects after the phone screening in case the research staff needs to
reschedule Visit 1 or for follow up if the subject does not show for the Visit 1. Because this study is recruiting using mass
email, subject information including a brief description why they were deemed ineligible (i.e. health history, medication,
breastfeeding) will be kept to prevent making contact twice with an individual who is ineligible. Information on why a
potential subject is ineligible/not passing the phone screening is to report to NIH and to monitor our recruiting progress.
Information on how the subjects heard of the study will help the research team understand the most successful methods
for advertising for the study. 
VII.D.23
Will this information be shared with anyone outside the UI research team members?
No
VII.D.25
After the subject agrees to participate (signs consent), are there any screening procedures, tests, or studies that need
to be done to determine if the subject is eligible to continue participating?
Yes
VII.D.26
List and describe screening
Medical history and physical exam
Resting blood pressure and heart rate


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
Standard blood chemistries (lipids, complete blood count, basic metabolic panel, liver enzymes)
Urine pregnancy test
VII.D.27
Discuss how much time a potential subject will have to agree to consider participation and whether or not they will be
able to discuss the study with family/friends before deciding on participation.
There is no time limit for the subject to agree to consider to be in the study as long as the study is actively recruiting subjects and
they are still eligible. Subjects are allowed to discuss the study with family/friends before deciding on participation.
VII.D.28
How long after the subject agrees to participate do study procedures begin?
The procedures in visit 1 (screening visit) can occur on the same day as consent. The experimental visits will begin within 2-3 weeks
or less of visit 1.
VII.D.29
Provide a description of the enrollment and consent process for adult subjects
Describe each study population separately including control population
Include when recruitment and consent materials are used
Use 3rd person active voice “The Principal Investigator will identify subjects. For example, the principal
investigator will identify potential subjects, the study coordinator will discuss the study with subjects over the
telephone and schedule the first study visit, etc...”
Describe the steps that will be taken by the research team to minimize the possibility of coercion or undue
influence during the consent process
The subjects will consist of healthy women (age 18 and older) who have delivered a baby within the past 2 years (24 months). The
control group will be women who have had a healthy pregnancy, with no history of cardiovascular or metabolic disease before or
during pregnancy. The preeclamptic group will be women who have had a preeclamptic pregnancy, but were free of cardiovascular or
metabolic disease prior to pregnancy. These subjects will be enrolled and complete salsalate and placebo treatments in a double-
blind randomized crossover design. The PI and research staff will recruit subjects from Johnson county and surrounding areas via
flyers, emails, The UI mass-email system, newspaper and newswire ads, and posting on the UIHC website for research volunteers.
Subjects will be asked to contact the research staff via phone or email. A study team member will then contact the potential
participant by phone to complete the phone screening and schedule visit 1 if they are eligible and wish to participate. Subjects will be
sent the consent summary either by e-mail or postal mail (subject preference) before visit 1. Visit 1 will include a detailed description
of the study and review of the informed consent, including risks. If subjects are not able to understand the protocol and instructions
for any reason, written or verbal, they are not included in the study. Subjects are informed throughout the consenting, screening,
and conduction of the study that they may discontinue their participation at any time with no penalty to them. If the subject signs
the informed consent, they are given a copy of the signed document to take home with them.
VII.D.37
Does the study include any form of deception (e.g., providing participants with false information, misleading
information, or withholding information about certain study procedures)?
Examples:
Procedure includes a cover story that provides a plausible but inaccurate account of the purposes of the research.
Participants will be provided with false information regarding the particular behaviors of interest in the research.
Procedures include a confederate pretending to be another participant in the study.
Participants will be told that the research includes completion of a particular task, when in fact, that task will not
be administered.
Study is designed to introduce a new procedure (or task) that participants are not initially told about.
If yes, a waiver of informed consent must be requested under question IV.3.
No
VII.E. Project Description (E)
VII.E.1
Will subjects be randomized?
Yes
VII.E.1.a
Will any subjects be blinded to which study arm they have been assigned?
Yes
VII.E.1.b
Does the protocol permit telling subjects their treatment assignment at the end of the entire study?
Yes
VII.E.1.c
Describe the circumstances under which subjects will be told what study arm they have been
assigned.
After the study is completed, subjects can be told which treatment they received at which visit if they wish to
know.
VII.E.2
Describe randomization scheme/assignment including ratio such as 1:1, 2:1 etc.
Subjects will be randomized to which treatment they receive first (placebo or salsalate). All subjects will complete both arms of
the study. They will be blinded to which treatment they are receiving at the time of the treatments. If they wish to know,
subjects can be informed which treatment they received at what time when they complete the study.
VII.E.3
Will any questionnaires, surveys, or written assessments be used to obtain data directly from subjects in this study?
Yes
VII.E.4
List all questionnaires, surveys, written assessments and ATTACH each one to the application. (NOTE: You are
NOT prohibited from attaching copyrighted materials to this application)


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
pre-consent screening survey
additional information survey 
health history questionnaire
VII.E.5
Does this project involve creating any audiotapes, videotapes, or photographs?
No
VII.E.6
Provide a detailed description in sequential order of the study procedures following the consent process - DO NOT cut
and paste from the Consent Document.
Describe study populations separately if they will be participating in different procedures - include CONTROL population
if applicable.
DESCRIBE:
What subjects will be asked to do/what happens in the study (in sequential order)
The time period over which procedures will occur
The time commitment for the subject for individual visits/procedures
Long-term followup and how it occurs
Visit 1 - Consent and Screening (approximately 1 hour)
The PI or research staff explain the study and go over the informed consent with the participant. After the participant signs the
informed consent, the PI or research staff performs the physical screening that includes urine pregnancy test, heart rate (HR), blood
pressure (BP), height, waist circumference, and weight measurements. The participant fills out the health history questionnaire. A
research nurse performs a standard venipuncture to obtain blood (total = 7.5ml blood) for complete blood count (CBC), chemistry
analysis, and lipid profile to be measured at UIHC pathology labs. 
Visits 2 and 4- Pick up study medications (approximately 15 minutes)
The PI or research staff give the participant study medication (salsalate or placebo). The PI or research staff goes over the
instructions for taking the study medication which includes how many pills to take and at what times of day, potential side effects,
and who to call if they have questions or problems while taking the medication. 
Visits 3 and 5 - Experimental visits (approximately 4 hours each)
Note: prior to coming to the Field House for the experimental visits, subjects take the oral study medication for 5 days. Subjects will
ingest 4 pills in the evening of Day 1, 4 pills in the evening and morning on Days 2,3, and 4, and 4 pills on the morning of Day 5, the
same day as the experimental visit (see drug info and schedule handouts). After the first study visit, subjects will undergo a washout
period of at least 14 days in which they do not ingest any study medication, before beginning the same 5 day regimen of the other
treatment. 
Experimental procedures
Subjects will come to the CRU where a research nurse performs a blood draw (14.5 ml, < 1 Tablespoon) for substances of interest
(e.g. inflammatory cytokines) and immune cell activity, salsalate level, creatinine, and blood urea nitrogen. Then the the subject will
be escorted by a member of the research team to 528 Field House for the intradermal microdialysis experiment. 
Intradermal microdialysis experiments will take place in 528 Field House. Please see the attached "intradermal microdialysis"
document for general information about intradermal microdialysis, schematic representation of the procedure, and references.
Microdialysis Probe Insertion: The researchers place a tight band around the forearm so they can visualize veins. For each MD site,
they make pairs of pen-marks on the arm 2.5 cm (1 inch) apart and away from veins. They remove the tight band. The MD tubing
enters and exits the skin at the marks. The researchers clean the arm with povidone iodine and alcohol, and place an ice bag on the
site for 5 minutes to numb the skin. Then they insert a thin needle into the skin at each entry mark. The needle’s tip travels between
the layers of skin for 2.5 cm (1 inch) and exits the skin at the matching exit-mark. They thread the microdialysis tubing through the
needle and then withdraw the needle leaving the tubing in the skin. Any hyperemia related to the insertion subsides in about 60
minutes. When the hyperemia induced by inserting the tubing in the skin subsides, the experiment begins.During this time Lactated
Ringer’s perfuses the tubing. The researchers tape a fiber optic laser Doppler flowmeter probe and its holder over each microdialysis
site. The researchers control the temperature of the holders. The holders start at 33°C (91.4°F). During the experiment, the
computerized data acquisition system records heart rate, sublingual temperature, skin blood flow, and skin temperatures
continuously. The researcher and/or an automated critical care monitor measures blood pressure at 5-7 minute intervals.
Acetylcholine and Angiotensin II Dose Responses: The intradermal microdialysis probes are randomly numbered 1 - 3 and assigned
to receive doses of acetylcholine with or without L-NAME (probes 1 and 2) or angiotensin II (probe 3). 
Acetylcholine Dose Response:	Microdialysis Probe 1. Lactated Ringer’s only
Microdialysis Probe 2. Lactated Ringer’s + L-NAME
Angiotensin II Dose Response:	Microdialysis Probe 3. Lactated Ringer’s only
When the skin blood flow is stable, the researchers perform a 10-minute baseline set of measurements. The researchers add identical
concentrations of acetylcholine to the perfusate in probes 1 and 2 and Angiotensin II to the perfusate in probe 3. At 5-minute
intervals, they increase the concentration of acetylcholine or angiotensin II in the perfusates. The participant receives 10 different
concentrations of acetylcholine and 9 different concentrations of angiotensin II. After perfusing the last concentrations, the
researchers warm the temperature controllers to 43°C (108°F) and switch perfusates at all sites to lactated Ringer’s for about 30
minutes. After 30 minutes they add SNP to the perfusates for approximately 5 minutes. Heating and SNP perfusion causes maximum
vasodilation at the microdialysis site. The researchers then de-instrument the subject, remove the microdialysis fibers, and apply
sterile dressings. The subject is given verbal and written instructions for how to care for the microdialysis sites. 
The researcher measures final vitals before the subject departs. At the end of visit 2, the subject is given instructions for the 14 day
washout period. The subject may be given the pills for the second treatment at the end of visit 2(replacing visit 4), along with
instructions for when and how to take the pills prior to study visit 5. 
VII.E.7
Will you attempt to recontact subjects who are lost to follow-up?


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
No - followup is not required in this study
VII.E.9
Will subjects be provided any compensation for participating in this study?
Yes
VII.E.10
Cash
No
VII.E.11
Gift Card
No
VII.E.12
Check
Yes
VII.E.13
Who will be providing the research compensation check to the subject?
Accounting Services directly via the e-Voucher system
VII.E.16
Other
Yes
VII.E.17
Describe:
Parking passes will be provided
VII.E.18
If you plan to compensate subjects using cash, checks or cash equivalent does your unit have a Cash
Handling Procedure in place that has been approved by Accounting Services?
Yes
VII.E.19
Describe the compensation plan including
Compensation amount and type per visit
Total compensation
Pro-rating for early withdrawal from study
Experimental visits: $75 per visit ($15/microdialysis probe + $7.50/hour for completing the experiment)
Total for completing the study: $150 (two completed study visits)
Parking pass for time involved at study and screening visits. 
Pro-rating: Subjects can receive payment for experiments not completed. The researchers pay an amount of money equal to
the part completed. For instance, if a subject completes half of Experiment 1, the subject receives $15.00 for each probe
inserted plus $7.50 for each hour they completed. The researchers may ask subjects to repeat a trial. If subjects agree to
repeat a trial, they receive payment for the repeated trial as stated above.
VIII. Risks
VIII.1
What are the risks to subjects including
- emotional or psychological
- financial
- legal or social
- physical?
Physical Risks:
Microdialysis: Intradermal microdialysis is a specialized research technique. Dr. Stanhewicz is highly skilled in this technique and has
been using the procedures in this protocol(including fiber placement, perfusate preparation, subject monitoring, and fiber removal)
for over 10 years with no adverse events (see letter of support from Dr. Lacy Alexander)and have been reviewed and approved by
Dr. Diana Jalal at the University of Iowa. Similar procedures for the use of intradermal microdialysis are used in other peer
institutions around the country (see letter's of support from Dr. Jody Greaney, Dr. Megan Wenner, and Dr. Chris Minson) without
regular adverse events. 
Cutaneous microdialysis commonly causes some pain and bruising similar to that experienced during venipuncture. There is usually
no pain after the probe is in place. The participant may experience mild pain while the researchers remove probe. Minor bleeding
may occur. As with any event that breaks the skin, infection is possible. However, no participants in any of the researchers’ prior
experiments have reported infection. In the unlikely event in which the membrane breaks during removal leaving an isolated piece of
membrane under the skin, they treat the piece of membrane in a manner similar to that for a splinter in the skin. In this case,
trained personnel make a superficial incision for removal. Such an event has never occurred in any projects overseen by Dr.
Stanhewicz. 
Microdialysis delivers small amounts of pharmacological substances to a nickel-sized area of the skin. The small quantities used and
the extremely localized administration during microdialysis does not produce systemic effects. To the researchers’ knowledge, there
are no reports of long or short-term side effects of these substances administered through microdialysis. The chance of adverse
reactions to these substances is extremely small given the minute amount delivered to the a very small area of skin, the lack of
adverse reactions to similar amounts delivered via MD in many other studies, and lack of adverse effects in human cell cultures.
There is a slight chance of allergic reaction to these substances that could produce redness, itching, rash, and/or swelling. 
Local Heating: The local heating control unit (Moor Instruments) precisely controls and monitors the temperature of the heated probe
holders used with the Laser Doppler Flowmeter. The system has programmed maximum temperature limits. To determine the
maximal SkBF, the researchers increase the temperature of the heating units slowly (about 0.1°C every 1 second). The skin feels
very warm but not painful. Local heating causes temporary redness of the skin that subsides within several hours. This technique is
very unlikely to produce long-term ill effects.


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
Povidone Iodine: Hospitals and researchers use povidone iodine to clean and sterilize the skin. Participants could be allergic to iodine.
An allergic reaction could cause redness, itching, rash, and/or swelling. Staff use only alcohol on participants with iodine allergy as
identified during screening.
Tape and adhesive disks: Participants could be sensitive to the adhesive of the tape, ECG electrodes, and double-sided adhesive disks
used in the study causing redness, rash, tenderness, and/or itching. The researchers remove these items carefully. 
Blood draws: Potential risks associated with obtaining blood samples are minimal but include slight bruising, pain, a temporary
feeling of faintness, and/or a small risk of infection. All blood draws will be performed by a research nurse or team member trained in
drawing blood. 
Salsalate: Salsalate is a non-steroidal anti-inflammatory drug (NSAID) in a group of drugs called salicylates. This medicine is used
clinically to reduce the pain, swelling, and joint stiffness caused by arthritis. 
The most common side effects from the Salsalate medication include (in order of decreasing frequency) tinnitus ('rininging in the
ears'), nausea, mild hearing impairment, rash, and vertigo in two studies with combined 280 subjects (percentages not available).
Another study of 782 patients with osteoarthritis or rheumatoid arthritis were treated with about 3000 mg/day for 3 weeks, 324
(41%) experience one or more side effects with 234 (30%) requiring discontinuation of Salsalate for GI side effects (13.2%), tinnitus
(6.7%), dizziness (1.7%) and 8.5% for other reasons. 
Metabolic acidosis: There is a very small risk of metabolic acidosis from salicylate toxicity although no clinical trials above reported
any incidence of this. This usually can be treated by stopping salsalate medication and with IV fluid and electrolyte therapy. 
Heart attack or stroke: Because Salsalate is an NSAID, people who take NSAIDs (other than aspirin) may have a higher risk of having
a heart attack or a stroke than people who do not take these medications. These events may happen without warning and may cause
death. This risk may be higher for people who take NSAIDs for a long time and in those who have cardiovascular disease. There is no
reported increased risk of heart attack or stroke in individuals on Salsalate so it cannot be determined what the exact risk (if any) is
for Salsalate at the dose and duration in this study. Subjects are instructed to get emergency medical help right away if they
experience any of the following symptoms during the study: chest pain, shortness of breath, weakness in one part or side of the
body, or slurred speech. 
Gastrointestinal bleeding: NSAIDs such as salsalate may cause ulcers, bleeding, or holes in the stomach or intestine. These problems
may develop at any time during treatment, may happen without warning symptoms, and may cause death. The risk may be higher
for people who take NSAIDs for a long time, are older in age, have poor health, smoke, or drink large amounts of alcohol or are on
the following medications: anticoagulants ('blood thinners') such as warfarin (Coumadin); aspirin; other NSAIDS such as ibuprofen
(Advil, Motrin) and naproxen (Aleve, Naprosyn); or oral steroids such as dexamethasone (Decadron, Dexone), methylprednisolone
(Medrol), and prednisone (Deltasone). All of these medication are exclusion criteria in our study. Subjects are instructed to stop
taking salsalate and call the study doctor if they experience any of the following during the study: severe stomach pain or heartburn,
vomiting a substance that is bloody or looks like coffee grounds, blood in the stool, or black and tarry stools. Because of this risk we
exclude for bleeding disorders and history of gastrointestinal bleeding.
Allergic reaction: Subjects could have a mild or severe allergic reaction including hives; difficult breathing; swelling of the face, lips,
tongue, or throat. We exclude subjects who have a known allergy to aspirin or NSAID.
Emotional or Psychological risks: There are no foreseeable psychological risks with this study. 
Social Risks: There are no foreseeable social risks with this study 
Legal Risks: There are no foreseeable legal risks with this study. 
Loss of confidentiality is possible. 
VIII.2
What have you done to minimize the risks?
If applicable to this study ALSO include:
How you (members of your research team at Iowa) will monitor the safety of individual subjects.
Include a description of the availability of medical or psychological resources that subjects might require as
a consequence of participating in this research and how referral will occur if necessary (e.g. availability of
emergency medical care, psychological counseling, etc.)
Note: All investigational substances used in these protocols are used with general Physician Oversight (see attached Standard
Operating Procedures document)
Risks Associated with Salsalate Treatment:
During the study if a subject experiences side effects that are life threatening, the subject will be instructed to call 911. If the subject
experiences any mild but tolerable expected side effects such as tinnitus, dizziness, nausea, headache, they will be asked to keep a
log of these including the date, the duration, and the severity by rating on a scale of 1 (mild) to 10 (severe/intolerable). If the
subject feels the side effects are uncomfortable or intolerable, then they will be instructed to call the Research Nurse or Dr.
Stanhewicz. The Research Nurse or Dr. Stanhewicz (although she will be blinded) will instruct the subject to skip the next dose and if
the symptoms/side effects have resolved at time of next dose (in 12 hours), they will be instructed to take the next dose. Dr.
Stanhewicz will consult with Dr. Jalal if necessary. If symptoms do not resolve or worsen at time of next scheduled dose, the subject
will be instructed to not take that dose, and to come to the CRU to have a blood sample to assess serum salicylate concentrations.
The subject will be withdrawn from the study procedures but will be followed up as necesary. If serum salicylate concentrations are
not in the toxic range (<30 mg/dl), the subject will be re-assessed in 12 hours to confirm that symptoms resolved. If blood plasma
salicylate concentrations are in the toxic range (>30 mg/dl), participants will return to the CRU in 12 hours for a follow-up blood draw
to confirm that salicylate values are decreasing and to reassess symptoms. Serum electrolytes, urinalysis and respirations may be
obtained in the case of suspected metabolic acidosis due to Salsalate toxicity. If metabolic acidosis is suspected, then Dr. Jalal will be
notified and determine appropriate medical management in the CRU or referral to the UIHC Emergency Department. 


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
Risks Associated with Intradermal Microdialysis:
Research techniques are only performed by personnel who are trained and approved by Dr. Stanhewicz to complete these
procedures. Dr. Stanhewicz has 10 years of experience utilizing intradermal microdialysis without unanticipated adverse events. All
laboratory personnel are trained in CPR and basic first aid. In the event of a life threatening emergency, lab personnel call 911. The
Field House is equipped with AED and lab personnel are trained in how to use them if necessary.
Prior to placing the microdialysis fibers, the researcher puts on sterile gloves and cleans the skin with iodine and alcohol to reduce
the risk of infection. The researchers apply ice to the skin for 5 minutes before placing the microdialysis fibers to reduce any pain
associated with placement. Once the fibers are in place, research personnel constantly monitor subjects for adverse reactions (e.g.
pain, itching, redness, swelling) to the microdialysis fibers or the perfusates. Participants are never left unsupervised with the fibers
in place. An automated monitor measures blood pressure every 5 minutes and constantly records heart rate. The researchers clip the
ends of the fibers and clean them with an alcohol swab before removing them from the skin to reduce the risk of infection. They stop
any bleeding by applying mild pressure to the sites with a sterile gauze pad. The researchers apply a clean, sterile bandage to the
area before the participant leaves. Participants are given verbal and written instructions on how to care for the sites and to call Dr.
Stanhewicz or the research nurse if they have any questions or concerns about the sites after they have left the study visit. 
Risk of loss of confidentiality: 
The investigators collect the minimum amount of confidential data in order to complete the aims. All subjects are assigned a code
and data and specimens are collected using the code only. The only time subject names and codes appear together is on their file
which is kept in a locked cabinet in the PI's office. Only IRB approved personnel have access to these files. All data files are stored on
password protected computers and servers and only IRB approved personnel have access. Extensive details on how the risk of loss of
confidentiality is minimized are provided in section X. Privacy and Confidentiality. 
VIII.3
Does this study have a plan to have an individual or committee review combined data from all subjects on a periodic
basis (such as summary or aggregate safety and/or efficacy data)?
Yes
VIII.4
Describe the plan to review combined data from all subjects, such as summary or aggregate safety and/or
efficacy data. Include the following:
Describe what data will be summarized and reviewed
Describe how frequently data will be reviewed.
The local Data Safety Monitoring Board performs bi-annual reviews of the study protocol, subject enrollment information, and
aggregate data collected to that point. The DSMB does not have access to individual identification of subjects. The DSMB then
makes recommendations regarding the progress of the study.
VIII.5
Will overall safety monitoring be performed by individual(s)/committee at The University of Iowa. (NOTE: If this
study involves more than minimal risk, in most cases these should be individuals who are not members of the
study research team.)?
Yes
VIII.6
List names:
Mark Santillan, MD; Melissa Swee, MD; Bridget Zimmerman, PhD
VIII.7
Will overall safety monitoring be performed by individuals or committee not associated with The University of
Iowa (such as a study Data Safety Monitoring Board)?
No
IX. Benefits
IX.1
What are the direct benefits to the subject (do not include compensation or hypothesized results)?
The study procedures and/or findings do not provide direct benefits to the subjects participating in the study. Subjects receive a
medical screening that could inform them about their health. They learn their blood pressure and blood cholesterol levels. This is
important knowledge. High blood pressure and blood cholesterol contribute to many serious health problems. We advise those with
high blood pressure or blood cholesterol to follow-up with a health care provider. They also learn of the connection between
preeclampsia and cardiovascular disease.
IX.2
What are the potential benefits to society in terms of knowledge to be gained as a result of this project?
Preeclampsia, a disorder of pregnancy effecting ~5-8% of pregnancies in the United States, and ~8 million pregnancies worldwide.
Otherwise healthy women who develop preeclampsia during pregnancy have 2-4 times greater risk for developing cardiovascular
disease later in life. Cardiovascular disease is the leading cause of death among women worldwide, a fact lending even more gravity
to the need for elucidating the mechanisms mediating the vessel dysfunction associated with preeclampsia and the increased risk for
cardiovascular disease. The information to be gained is essential to the understanding of the related cardiovascular pathology. This
knowledge could suggest and aid the development of novel therapeutic strategies for the management of risk in this population.
X. Privacy & Confidentiality
X.1
What are you doing to protect the privacy interests of the subjects?
The minimum amount of data necessary to complete the aims will be collected during the study. The informed consent process will
be conducted in a private exam room in the CRU with the door closed. All screening and experimental procedures will be conducted in
the laboratory in 528 FH with the door closed and locked. Only personnel directly involved in the study will be allowed in the rooms.
X.2
Are you collecting the Social Security Number of any subjects for any purpose?


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
No
X.4
How will information/data be collected and stored for this study (check all that apply):
Electronic records (computer files, electronic databases, etc.)
- Data will be entered using subject ID code into the ICTS
REDCap web-based database application that is password protected. No personal identifiable data will be entered. Only
research staff on the IRB approved study will be allowed access this database. The ICTS REDCap staff are responsible for
maintaining security of the data. Some data using subject ID code will also be entered into a Microsoft Excel and SPSS
datasheets that will be kept in a shared server for CLAS that is password protected. Only research staff on the IRB approved
study will have access to the folder the study on the server.
Name - Bryan Ringen
Title - IT Support Consultant
University Job Classification - Faculty/Staff
Paper/hard copy records (hard copy surveys, questionnaires, case report forms, pictures, etc.) - Most of the data are coded
and do not contain personal identifying information. Some data will temporarily contain the subject’s name, address, and/or
telephone number (Phone Interview Form). Documents allowing identification of participants do not leave our labs and are only
available to authorized persons. Only authorized personnel may access the lab computer. Data forms containing identifiable
information are shredded when no longer needed (within 5 years after publication of results). We keep data in the laboratory in
locked cabinets, the password-protected folder on the secured University of Iowa RDSS server, and on password-protected
computers maintained in locked laboratory rooms. Only authorized personnel have access. Coded data shared with
unauthorized persons cannot be traced to individuals. The list linking code numbers to participants is not shared with
unauthorized persons and destroyed when the project is completed and within 5 years of publication of the data.
Screening
data from subjects who are not accepted into the study are shredded when the project ends. Subjects may give permission to
have their contact information retained in the investigator’s secured files if they wish to be considered for participation in future
studies. After we complete the study, we remove all identifiers from the data and store the data indefinitely. Individual data
may be used without identifying the subject to illustrate representative responses.
Any hard paper copy of subject lists or data
will be kept in a locked cabinet in the locked office of the PI. Subjects will be assigned a code for the study. Files will be labeled
with this code for confidentiality. Study data including laser-Doppler flowmetry data will be stored on password protected
computer hard-drives and password protected server folders which are only accessible to research team members via
password. Subject confidentiality will be maintained in all presentations and publications and information/records pertaining to
subject participation in the research project will not be released without prior authorization by the subjects.
Biologic samples (blood draws, check swabs, saliva samples, tissue samples, etc.)
- Basic blood chemistries will be sent to the
UIHC pathology lab for analyses. Remaining biological specimens, such as blood, will be labeled with subject code, date
collected and IRB protocol number and transported to the PIs laboratory (528 Field House) in a secure unbreakable biohazard
container. Samples will be stored in the PIs laboratory in a -80C freezer in S503 FH. All samples will be labeled with date
collected and subject ID code only. No personal identifiable information will be labeled on the sample. Only the PI and her
research staff will have access to the samples.
Name - Anna Stanhewicz
Title - Assistant Professor
University Job Classification - Faculty/Staff
X.5
Do the confidentiality protections indicated above allow only members of the research team to access the
data/specimens?
Yes
X.7
Does your study meet the NIH criteria for a Certificate of Confidentiality or will you be applying for Certificate of
Confidentiality?
Yes
X.8
If yes, provide rationale:
Per Section 2012 of the 21st Century Cures Act as implemented in the 2017 NIH Certificates of Confidentiality Policy, all
ongoing or new research funded by NIH as of December 13, 2016 that is collecting or using identifiable, sensitive information is
automatically issued a CoC.
XI. Data Analysis
XI.1
Describe the analysis methods you will use, including, if applicable, the variables you will analyze
The primary outcome variable will be cutaneous vascualr conductance, which is calculated from laser-Doppler flux/mean arterial
pressure. Three-way repeated measures analysis of variance will be performed to examine group differences (PrEC vs. control) or
systemic treatment differences (salsalate vs. placebo), and local microdialysis treatment differences across the doses of
pharmacological stimuli. Appropriate post-hoc analyses with corrections for multiple comparisons will be performed when main effects
are identified, including potential confounding variables as covariates.
XI.2
Provide the rationale or power analysis to support the number of subjects proposed to complete this study.
Using previously published data with similar primary outcomes we determined by power analysis (2 group ANOVA, power=0.80,
α=0.05) that 12 subjects per group will be sufficient to measure a meaningful physiological difference of at least 15% between
microdialysis sites (within-subject comparison) and groups (between subject comparisons). Conservatively, we recommend
increasing to 16 subjects per group to account for potential dropout during the salsalate trials.
XII. Future Research
XII.1
Do you wish to keep any information about subjects involved with this research project so that members of the current
research team may contact them in the future for your own research projects?
Yes
XII.2
Do you wish to keep any information about subjects involved with this research project so that other researchers may


HawkIRB
file:///C/Users/astanhewicz/OneDrive%20-%20University%20of%20Iowa/Salsalate/HawkIRB_201909818.html[7/14/2020 10:47:57 AM]
contact them for future research?
No
XII.3
List the data or information you will keep:
Name
Race/ethnicity
Age
Pregnancy history
Contact information (mailing address, e-mail address, phone number) 
XII.4
Does this project involve storing any data, tissues or specimens for future research?
Yes – contribution for future use is optional
XII.5
Describe how you will keep track of those who consent to future use and those who do not and how you will
prevent future use for those who do not consent.
We will keep track of who consents to future use on our enrollment log.

ICF_001.pdf: 
College of Liberal Arts  
and Sciences 
Department of Health and Human 
Physiology 
University of Iowa 
E102 Field House 
Iowa City, Iowa 52242-1111 
319-384-4664   Fax 319-335-6669 
 
 
 
 
 
 
Document date: Approved by IRB September 24, 2020 
 
Project title: Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction 
Following Preeclampsia 
 
NCT #: 03482440 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
P a ge 1 of 1 2  
I N F O R M E D C O N S E N T D O C U M E N T 
Pr oject Title:  
R ole of a n gi ote nsi n II a n d i nfl a m m ati o n i n persiste nt vessel d ysf u ncti o n f oll o wi n g 
preecl a m psi a  
Pr i nci p al I n vesti g at or: 
A n n a St a n h e wi c z , P h D 
Res e arc h Te a m C o nt act:  
A n na Sta n he wicz, P h D 
4 1 0 Fiel d H o use 
2 2 5 S o ut h Gra n d A ve n ue 
I o wa Cit y, I A 5 2 2 4 2 
P h o ne: ( 3 1 9) 4 6 7- 1 7 3 2  
E- mail: a n na -sta n h e wicz @ ui o wa.e d u
T hi s c o nse nt f or m descri bes t he resear c h st u d y t o hel p y o u deci de if y o u w a nt t o partici pate.  T his f or m 
pr o vi des i m p orta nt i nf or mati o n a b o ut w hat y o u will be as ke d t o d o d uri n g t he st u d y, a b o ut t he ris ks a n d 
be nefits of t he st u d y, a n d a b o ut y o ur ri g hts as a researc h s u bject.   
•
If y o u ha ve a n y q uesti o ns a b o ut or d o n ot u n derst a n d s o met hi n g i n t his f or m, y o u s h o ul d as k
t he researc h tea m f or m ore i nf or mati o n.
•
Y o u s h o ul d disc uss y o ur partici pati o n wit h a n y o ne y o u c h o ose s uc h as fa mil y or frie n ds.
•
D o n ot a gree t o p artici pat e i n t his st u d y  u nless t he researc h tea m has a ns w ere d y o ur
q uesti o ns a n d y o u deci de t hat y o u wa nt t o be part of t his st u d y.
W H A T I S T H E P U R P O S E O F T HI S S T U D Y ?  
T hi s is a researc h st u d y.  We ar e i n viti n g y o u t o partici pate i n t his researc h st u d y beca use y o u h a d a 
preecl a m ptic pre g na n c y i n t he past 2 years or beca use y o u ha d a n u n c o m plicate d pre g na nc y i n t he p ast 2 
years.  
T he  p ur p ose of t his r esearc h st u d y is t o u n dersta n d h o w a hist or y of preecl a m psia affects bl o o d vessel 
f u ncti o n. Preecl a m psia ma y ca use h ar mf ul c h a n ges t o bl o o d vessels t hat last a lifeti me a n d lea d t o 
car di o vas c ular disease .  T he c ha n g es affect h o w t he b o d y c o ntr ols bl o o d fl o w.  T his researc h st u d y l o o ks 
at h o w t hese c h a n ges occ ur i n w o me n w h o ha d preecla m psia.  T o d o t his, w e c o m pare t he c o ntr ol of 
bl o o d fl o w i n t he s ki n of w o me n w h o ha d preecla m psia wit h t hat of w o me n w h o di d n ot ha ve 
preecl a m psia .   
T hi s st u d y i ncl u des t he use of s o me res earc h dr u gs i n a nic kel-size d area of s ki n o n y o ur ar m 
(acet ylc h oli ne, L- N A M E, a n gi ote nsi n II, a n d s o di u m nitr o pr ussi de) a n d a st u d y me dicati o n t hat is ta ke n 
orall y (salsalate c o m par e d t o place b o). T h e dr u gs are n ot a p pr o ve d b y t he F D A t o treat disease.  
H o we ver, t he F D A has a p pr o ve d o ur usi n g t he dr u gs i n t his st u d y.  
H O W M A N Y P E O P L E WI L L P A R TI CI P A T E ?  
A p pr o xi matel y 4 0 pe o ple will ta ke part i n t his st u d y c o n d ucte d b y i n vesti gat ors at t he U ni versit y of 
I o wa. 
H O W L O N G WI L L I B E I N T HI S S T U D Y ?  


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 2 of 1 2  
If y o u a gr ee t o ta ke p art i n t his st u d y, y o ur i n v ol ve me nt will last f or a p pr o xi matel y 6 wee ks. D uri n g 
t h ose 6 wee ks y o u will visit t he UI ca m p us 4-5 ti mes .  
1.  Scree ni n g visit   
 
u p t o 1 h o ur  
2.  Pic k u p pretre at m e nt 1   
1 5 mi n utes 
3.  St u d y Visit 1     
 
u p t o 4 h o urs  
 
After st u d y visit 1 y o u will ha ve a t w o-wee k  was h o ut peri o d w here y o u d o n ot ta ke a n y st u d y 
me dicati o ns  b ut y o u are still e nr olle d i n t he st u d y.  
4.  Pic k u p pretre at m e nt 2   
1 5 mi n utes (ca n be c o m plete d at t he e n d of st u d y visit 1) 
5.  St u d y Visit 2     
 
u p t o 4 h o urs  
 
W H A T WI L L H A P P E N D U RI N G T HI S S T U D Y ?  
Scree ni n g:  T he r esearc h ers a n d/ or Cli nical Researc h U nit  ( C RU) staff p erf or m t he scree ni n g.  T he 
researc hers meas ur e y o ur hei g ht a n d wei g ht, bl o o d press ure ( B P), a n d heart rate ( H R).  T h e y meas ure 
waist circ u mfere n ce.  Y o u fill o ut a healt h hist or y q uesti o n naire. Y o u ca n s ki p a n y q uesti o ns t hat y o u d o 
n ot wa nt t o a ns wer. T h e C R U  staff dra ws 5 0 ml ( < 4 T bs p) of bl o o d fr o m a vei n i n y o ur ar m.  We se n d 
s o me of t he bl o o d t o a la b t o see if t he pr otei ns, bl o o d cells, electr ol ytes, etc. are wit hi n n or mal le vels. 
Y o u s u b mit a uri ne sa m ple f or a pr e g na n c y test. We will use t he i nf or mati o n c ollecte d d uri n g t he 
scree ni n g visit t o deter mi ne if y o u ar e eli gi ble t o c o nti n ue i n t he st u d y, a n d t o a nal yze o ur d ata i n t he 
st u d y. After t he scree ni n g visit, if y o u are eli gi ble t o c o nti n ue i n t he st u d y y o u be gi n ta ki n g t he 
pretreat me nt.  
 
Pret re at m e nts:  We assi g n o ne of t he pr etreat me nts (salsalate or place b o) f or y o u t o ta ke f or 5 da ys. T he 
c h oice of t he first treat m e nt is ra n d o m.  
a. T he salsalat e d ose is 3 0 0 0 m g/ da y ( 1 5 0 0 m g t wice dail y) f or 5 d a ys. O n t he first da y 
y o u o nl y ta ke o ne d ose i n t he e ve ni n g a n d o n t he last da y y o u o nl y ta ke o n e d ose i n t he 
m or ni n g.  
b. Y o u c o me t o t he la b t o pic k u p t he s alsalate pills. Y o u ta ke a uri n e pre g n a nc y test. If 
t he test is p ositi ve we d o n ot gi ve y o u t he pills a n d y o u are wit h dra w n fr o m t he st u d y. 
c. T he n urse dra ws a bl o o d sa m ple ( 3 0 ml, < 2. 1 T bs p) f or s alsalat e, creati ni ne, B U N 
le vels, a n d s u bsta nces of i nterest o n t he da y(s) of t he e x peri me nts. 
 
* * N ote: If t he ser u m salsalate c o n ce ntrati o n i n y o ur bl o o d is > 3 0 m g/ dl, we will as k y o u t o ret ur n t o t he 
la b o ne wee k later f or a bl o o d dra w ( 1 0 ml, 0. 7 T bs p) t o e ns ure Salic ylate, creati ni ne, a n d B U N ha v e 
ret ur ne d t o n or mal. 
 
•  We d o n ot wa nt y o u t o k n o w t he i de ntit y of t he pill y o u are ta ki n g w hile y o u are acti ve i n t he st u d y. 
•  After 5 da ys of ta ki n g t he first pretr eat me nt, y o u c o me t o t he la b f or t h e e x peri me nts descri b e d 
bel o w. 
•  T he n y o u ta ke n o pr etreat me nts ( was h o ut) f or at least 1 4 da ys. 
•  Y o u ta ke t he sec o n d pretreat me nt f or 5 d a ys. 
•  After 5 da ys of ta ki n g t he sec o n d pr etreat me nt, y o u c o me t o t he la b t o re p eat t he e x p eri me nts 
descri be d b el o w.  
 
Micr o di al ysis E x peri me nts:   
Bef ore y o u arri ve:  


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 3 of 1 2  
If y o u ha ve q uesti o ns a b o ut t he st u d y, please c o ntact us ri g ht a wa y. Y o u d o n ot eat or dri n k 
a n yt hi n g c o ntai ni n g caffei ne (e x. c offee, tea, C oca C ola, c h oc olate) f or 1 2 h o urs bef ore t he 
e x peri me nt a n d d o n ot perf or m stre n u o us p h ysical acti vit y f or 2 4 h o urs bef ore t he e x peri me nt.  
 
W he n y o u arri ve:  
T he researc hers meet y o u i n t he Cli nical Researc h U nit of t he U ni versit y of I o wa H os pital.  We 
meas ure y o ur bl o o d press ure, heart rate, a n d oral te m perat ure. A C R U n urse dra ws y o ur bl o o d 
a n d t he n we wal k o ver t o t he File d H o use f or t he e x peri me nt.  
 
Micr o di al ysis ( M D):  
O ver vie w:   M D i n v ol ves placi n g ver y t hi n plastic t u bi n g bet wee n t he la yers of y o ur s ki n.  T he 
lar gest part of t he t u bi n g is a b o ut 6 ti mes t he dia meter of a h u ma n hair.  We p u m p fl ui d li ke t hat 
f o u n d i n y o ur b o d y’s tiss ues (lactate d Ri n ger’s s ol uti o n) t hr o u g h t he t hi n t u bi n g.  T he t hi n t u bi n g 
acts li ke t he ver y s mall bl o o d vessels i n y o ur s ki n.  T here is a n e xc ha n ge of s u bsta nces bet wee n 
t he fl ui d i n t he t u bi n g a n d t he fl ui d i n t he s urr o u n di n g tiss ue.  D uri n g t he e x peri me nt, we a d d 
s u bsta nces t o t he fl ui d i n t he t u bi n g.  T he s u bsta nces ca n o nl y reac h a 2. 5 c m 2 ( 0. 4 i nc h2), nic kel-
size d area of s ki n. 
 
M D Pr o be I nserti o n:   We place a ti g ht ba n d ar o u n d y o ur ar m s o we ca n easil y see y o ur vei ns.  
F or eac h M D site, we ma ke pairs of pe n -mar ks 2. 5 c m ( 1 i nc h) a part a n d a wa y fr o m vei ns.  T he 
M D t u bi n g e nters a n d e xits y o ur s ki n at t he mar ks.  We re m o ve t he ti g ht ba n d.  We clea n y o ur 
ar m wit h a n ora n ge-c ol ore d fl ui d a n d alc o h ol.  We place a n ice ba g o n y o ur ar m f or 5 mi n utes t o 
n u m b y o ur s ki n.  T he n we i nsert a t hi n nee dle i nt o y o ur s ki n at eac h e ntr y mar k.  T he nee dle’s ti p 
tra vels bet wee n t he la yers of s ki n f or 2. 5 c m ( 1 i nc h).  It lea ves y o ur s ki n at t he matc hi n g e xit 
mar k.  We t hrea d t he M D t u bi n g t hr o u g h t he nee dle.  Ne xt, we wit h dra w t he nee dle lea vi n g t he 
t u bi n g i n y o ur s ki n.  We pre pare all M D sites i n t his ma n ner.  A n y re d ness of y o ur s ki n s u bsi des 
i n a b o ut 6 0 – 1 2 0 mi n utes.  
 
Me as ure me nts:  
Bl o o d  Press ure,  Heart  Rate:   We  meas ure  bl o o d  press ure  a n d  heart  rate  t hr o u g h o ut  t he  
e x peri me nt.  We a p pl y t hree stic k y ta bs t o t he s ki n of y o ur c hest.  T he ta bs c o n nect t o a n E C G 
mac hi ne t hat rec or ds heart rate.  D uri n g t he e x peri me nt, we ca n meas ure bl o o d press ure i n a n y of 
t w o wa ys.  a)  We i nflate a c uff o n y o ur u p per ar m w hile we liste n at t he i nsi de of y o ur el b o w 
wit h a stet h osc o pe.  b)  Li ke wise, a n a ut o mate d mac hi ne i nflates a c uff o n t he u p per ar m a n d 
uses a se ns or i n t he c uff t o meas ure bl o o d press ure.  
 
S ki n  Bl o o d  Fl o w,  S ki n  Te m perat ure :   We  meas ure  s ki n  bl o o d  fl o w  a n d  s ki n  te m perat ure  
t hr o u g h o ut t he e x peri me nt.  We ta pe a t hi n pr o be a n d its h ol der o ver fi ve sites o n y o ur f orear m.  
T he t hi n pr o be meas ures s ki n bl o o d fl o w wit h a wea k laser li g ht.  T he h ol ders meas ure s ki n 
te m perat ure.  We c o ntr ol t he te m perat ure of t he h ol ders.  T he h ol ders start at 3 4° C ( 9 3° F). 
 
E x peri me nt Pr ot oc ol:  
We pre pare 3 M D sites as descri be d a b o ve.  
Acet ylc h oli ne D ose Res p o nse:  
Pr o be 1. Lactate d Ri n ger’s o nl y  
    
  
 
Pr o be 2. Lactate d Ri n ger’s + L -N A M E  
A n gi ote nsi n II D ose Res p o nse:  
Pr o be 3. Lactate d Ri n ger’s o nl y  


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 4 of 1 2  
 
a. At first, Lactate d Ri n ger’s o nl y fl o ws t hr o u g h all pr o bes.   
b.  T he n t he L -N A M E is a d de d t o t he Lactate d Ri n ger’s fl o wi n g t hr o u g h M D pr o be f or 3 0 mi n utes.  
c. W he n s ki n bl o o d fl o w is sta ble, we c ollect baseli ne data f or 2 0 mi n utes.   
d.  Pr o bes 1 -2:  At 5 -mi n ute i nter vals, we i ncrease t he a m o u nt of acet ylc h oli ne i n t he fl ui d. Y o u 
recei ve 1 0 differe nt a m o u nts of acet ylc h oli ne. 
e. Pr o bes 3:  At 5 -mi n ute i nter vals we i ncrease t he a m o u nt of a n gi ote nsi n II i n t he fl ui d. Y o u 
recei ve 9 differe nt a m o u nts of a n gi ote nsi n II.   
f. After t he last a m o u nts of acet ylc h oli ne or a n gi ote nsi n II we war m t he te m perat ure c o ntr ollers t o 
4 3° C ( 1 0 8° F) a n d s witc h t he fl ui d at all sites t o Ri n ger’s. After 4 0 mi n utes of heati n g we a d d 
S N P t o t he fl ui d i n sites 1 a n d 2 f or 5 mi n utes.  
g.  We re m o ve t he M D pr o bes a n d a p pl y a sterile dressi n g.  If y o u wa nt, we ca n place a ba g of ice 
o n  y o ur  ar m  f or  1 0  mi n utes  t o  re d uce  a n y  br uisi n g  t hat  ma y  occ ur.   We  re m o ve  all  
i nstr u me ntati o n. 
h.  We meas ure y o ur bl o o d press ure a n d heart rate bef ore y o u lea ve.  
 
 
Tiss ue / Bl o o d/ D at a St or a ge f or F ut ure Use   
As  part of t his st u d y, we are o btai ni n g bl o o d sa m ples a n d peri p heral bl o o d m o n o n uclear cells ( w hite 
bl o o d cells circ ulati n g i n y o ur bl o o d) fr o m y o u. We w o ul d li ke t o st u d y y o ur bl o o d sa m ples a n d 
m o n o n uclear cells  i n t he f ut ure, aft er t his st u d y is o ver. Y o ur s a m ple, i nf or mati o n, a n d/ or data ma y be 
place d i n a ce ntral r e p osit or y or ot her nati o nal re p osit ories s p o ns ore d b y t he Nati o nal I nstit utes of 
Healt h or ot her Fe d eral a ge ncies. If t his ha p p e ns, it ma y be stri p pe d of i de ntifiers (s uc h as n a me, dat e of 
birt h, a d dress, etc).  Ot her q ualifie d res ear c hers w h o o btai n pr o per per missi o n ma y gai n access t o y o ur 
sa m ple a n d/ or data f or us e i n a p pr o ve d researc h st u dies t hat ma y or ma y n ot be relate d t o i n t he p ur p ose 
of t his st u d y.   
  
Bl o o d cells re m o ve d fr o m t he bl o o d sa m ples ma y be use d t o ma ke a cell li ne a n d D N A  or c o n d u ct 
w h ole ge n o me se q u e nci n g. Cell li nes are pr o d uce d b y gr o wi n g bl o o d cells i n a la b orat or y a n d all o w us 
t o ha ve a s o ur ce of t he D N A wit h o ut ha vi n g t o re dra w y o ur bl o o d. T h ese bl o o d cells ca n be st ore d f or 
deca d es or m ore. T h e cell li nes, D N A, a n d/ or ge n o me se q ue nci n g res ults a n d data will be ma de 
a vaila ble t o res ear c hers tr yi n g t o lear n m ore a b o ut t he ca use of diseases.    
 
Eac h of t he cells i n y o ur b o d y c o ntai ns D N A. D N A is t he i nstr ucti o n ma n ual t hat deter mi nes y o ur 
a p pear a nce i n t hi n gs li ke e ye c ol or or h o w tall y o u ca n be. Y o ur D N A m a y als o lea d t o hi g her or l o w er 
ris k of cert ai n diseases. Y o ur e n vir o n me nt will als o deter mi ne s o me of y o ur disease ris k.   
 
Y o ur D N A is a stri n g of f o ur b uil di n g bl oc ks, calle d “ bases. ” T hes e bases are re pres e nte d b y t he letters 
G, A, T, a n d C.  T her e ar e billi o ns of t hese letters str u n g t o get her i n e ver y h u ma n’s D N A a n d t h e y are 
arra n g e d i n pac k a ges li ke w or ds. Eac h of t hese “ w or ds” ha ve s p ecific j o bs i n t he b o d y.  M ost of t he ti me 
t he letters ar e t he sa me i n e ver y o ne. B ut a b o ut 1 % of t he p o p ulati o n mi g ht ha ve a n “ A” w h ere s o m e o ne 
else has a “ G.” T his diff ere nce ca n e x plai n w h y s o me pe o ple ha v e bl ue e y es a n d ot hers br o w n e yes, or 
w h y s o me ha ve a hi g h ris k f or a certai n ca ncer a n d ot hers a l o w ris k. All t hese letters c o me t o get h er t o 
creat e y o ur “ g e n o me se q ue nce”, a ki n d of b o o k of y o ur ge netics.  It n o w p ossi ble t o rea d off eac h of 
t hese letters a n d rea d y o ur c o m plete ge n o me s e q ue nce.  Y o ur D N A se q u e nce is u ni q ue t o y o u. Y o u 
i n herit y o ur D N A i n al m ost e q ual parts fr o m eac h of y o ur pare nts.  I n ver y rare cases, y o ur ge n o me ca n 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 5 of 1 2  
als o c ha n ge t hr o u g h “ m utati o ns.” A m utati o n is li ke if y o u trie d t o c o p y a pa ge fr o m a b o o k, b ut 
miss pelle d s o me w or ds. M utati o ns us uall y res ult fr o m c o p yi n g err ors t hat occ ur i n certai n letters w he n 
bei n g passe d fr o m p are nt t o c hil d.  
  
W he n we t a ke a s a m ple of y o ur bl o o d/tiss ue f or t his st u d y, it ma y g o t o a la b t o rea d off t h ose letters a n d 
gi ve us a re p ort o n y o ur ge n o me.  T his i nf or mati o n will t he n be c o m pare d wit h ot her ge n o mes t o see 
h o w t he y ma y be t he sa m e or differe nt.  It is o ur h o pe t his will hel p us t o better u n dersta n d h o w t he 
h u ma n b o d y w or ks a n d/ or w hat ca us es it t o n ot w or k well, as w he n s o m e o n e has a disease. 
 
T he tests we mi g ht wa nt t o use t o st u d y y o ur bl o o d a n d m o n o n uclear cells  ma y n ot e ve n e xist at t his 
ti me.  T heref ore, w e ar e as ki n g f or y o ur per missi o n t o st ore y o ur bl o o d a n d m o n o n uclear cells s o t hat we 
ca n st u d y t he m i n t he f ut ure.  T hese f ut ure st u dies ma y pr o vi de a d diti o nal i nf or mati o n t hat will be 
hel pf ul i n u n dersta n di n g preecl a m psia a n d car di o v asc ular disease, b ut it is u nli kel y t hat w hat we lear n 
fr o m t hese st u dies will ha ve a dir ect be n efit t o y o u.  It is p ossi ble t hat y o ur bl o o d a n d m o n o n uclear cells 
mi g ht be use d t o de vel o p pr o d ucts tests, or disc o v eries t hat c o ul d be p ate nt e d a n d lice nse d.  I n s o me 
i nsta nces, t hese ma y h a v e p ote ntial c o m merci al val ue a n d ma y b e de vel o p e d b y t he I n vesti gat ors, 
U ni versit y of I o wa, c o m mercial c o m pa ni es, or ga nizati o ns f u n di n g t his researc h, or ot hers t hat ma y n ot 
be w or ki n g directl y wit h t his resear c h tea m.  H o w e ver, d o n ors of bl o o d a n d m o n o n uclear cells  d o n ot 
retai n a n y pr o p ert y ri g hts t o t he materials.  T heref ore, there  are n o pla ns t o pr o vi de fi na nci al 
c o m pe nsati o n t o y o u s h o ul d t his occ ur.   
 
Y o ur bl o o d a n d m o n o n u clear cells will be st ore d wit h a c o de w hic h m ay b e li nke d t o y o ur na me a n d date 
of birt h. If y o u a gree n o w t o f ut ure use of y o ur bl o o d a n d m o n o n uclear cells b ut deci de i n t he f ut ure t hat 
y o u w o ul d li ke t o ha ve it re m o ve d fr o m f ut ure researc h, y o u s h o ul d c o ntact A n na Sta n he wicz ( 3 1 9- 4 6 7-
1 7 3 2, a n na-sta n h e wicz @ ui o wa.e d u). H o we ver , if s o me researc h wit h y o ur bl o o d a n d m o n o n uclear cells 
has alrea d y bee n c o m plet e d, t he i nf or mati o n fr o m t hat researc h ma y still be use d.  
 
Ple ase pl ace y o ur i niti als i n t he bl a n k ne xt t o Yes or N o f o r e ac h of t he q uesti o ns bel o w: 
 
M y bl o o d a n d m o n o n ucle ar cells  m a y be st ore d/s h are d f or f ut ure rese a rc h i n c ar di o v asc ul ar 
dise ase, preecl a m psi a, etc.  
 
_ _ _ _ _ Yes   
_ _ _ _ _ N o 
 
M y bl o o d a n d m o n o n ucle ar cells  m a y be st ore d/s h are d f or f ut ure rese a rc h f or a n y ot her p ur p ose . 
 
_ _ _ _ Yes   
_ _ _ _ N o 
 
WI L L I B E N O TI FI E D I F M Y S T U D Y VI SI T R E S U L T( S) I N A N U N E X P E C T E D FI N DI N G ?   
T he res ults fr o m t he s ki n bl o o d fl o w data  we c ollect i n t his researc h st u d y are n ot t he sa me q u alit y as 
w hat y o u w o ul d recei ve as part of y o ur r o uti ne healt h care. T he res ults will n ot be re vie w e d b y a 
p h ysicia n w h o n or mall y rea ds s uc h res ults. D ue t o t his, y o u will n ot be i nf or me d of a n y u n e x pect e d 
fi n di n gs. T he res ults of y o ur st u d y visit will n ot be place d i n y o ur m e dical rec or d wit h y o ur pri mar y care 
p h ysicia n or ot her wise. If y o u belie ve y o u are ha vi n g s y m pt o ms t hat ma y re q uire care, y o u s h o ul d 
c o ntact y o ur pri mar y car e p h ysicia n. 
 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 6 of 1 2  
If y o u c o nse nt, w e ma y c o ntact y o u t o partici pate i n f ut ure st u dies wit h o ur la b orat or y gr o u p. We will 
kee p y o ur na m e, race/et h nicit y, a ge, pre g n a nc y hist or y, a n d c o ntact i nf or mati o n f or t his p ur p ose. 
Partici pati n g i n t his st u d y d oes n ot mea n t hat y o u are o bli gate d t o partici pate i n a n y f ut ure st u dies. A 
se parat e c o nse nt d oc u m e nt w o ul d be si g ne d f or f ut ure st u dies.   
 
Ma y we kee p y o ur na m e, race/ et h nicit y, a ge, pre g na nc y hist or y, a n d c o nt act i nf o t o c o ntact y o u f or 
f ut ure st u dies? Please c h ec k o ne: 
  
 
  Y E S  
  
 
  N O  
 
 
W H A T A R E T H E RI S K S O F T HI S S T U D Y ?  
Y o u ma y e x perie nce o n e or m ore of t he ris ks i n dicate d bel o w fr o m bei n g i n t his st u d y. I n a d diti o n t o 
t hese, t here m a y be ot her u n k n o w n ris ks, or ris ks t hat we di d n ot a ntici pate, ass ociate d wit h bei n g i n t his 
st u d y.  


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 7 of 1 2  
 
Micr o di al ysis:   T he ris ks are less t ha n t hat f or a bl o o d dra w beca use micr o dial ysis uses o nl y a s mall, 
l ocal area of s ki n.  I n c o ntrast, a bl o o d dra w i n v ol ves n ot o nl y s ki n, b ut als o lar ge bl o o d vessels a n d 
bl o o d.  Y o u are li kel y t o ha ve s o me pai n a n d br uisi n g li ke t hat fr o m a bl o o d dra w.  H o w e ver, we use ice 
t o n u m b y o ur ar m w he n we i nsert t he t u bi n g.  Als o, t he s mall nee dle re d uces pai n w he n w e i nsert t h e 
t u bi n g.  Y o u are n ot li kel y t o ha ve pai n aft er t he t u bi n g is i n place.  Y o u ma y feel a little pai n w he n we 
re m o ve t he t u bi n g fr o m y o ur s ki n.  Nee dles ma k e s o me pe o ple feel li g ht hea de d or ca use t he m t o fai nt.  
Alt h o u g h rare, t he t u bi n g c o ul d brea k as we re m o ve it fr o m t he s ki n.  T he n we re m o ve t h e t u bi n g still i n 
y o ur s ki n b y p ulli n g o n t he ot her e n d of it.  T his prese nts n o a d d e d ris k f or y o u.  E ve n m ore rare, t h e 
t u bi n g c o ul d brea k s o t hat a piece of t h e t u bi n g is left u n der y o ur s ki n.  I n t his case, we treat a n y t u bi n g 
still i n y o ur s ki n li ke a s pli nter.  We st o p a n y mil d blee di n g wit h mil d press ure a n d sterile g a uze.  
I nfecti o n is p ossi ble.  We kee p t he ris k of i nfecti o n ver y s mall b y usi n g sterile tec h ni q ues a n d s u p plies 
li ke t h ose use d wit h bl o o d dra ws.  We a p pl y a sterile ba n da ge t o t he site after t he e x p eri me nt.  We tell 
y o u h o w t o ta ke care of t he site.   
 
Fl ui d fl o wi n g t hr o u g h t he t u bi n g:   T he s u bsta nces fl o wi n g t hr o u g h t he t u bi n g o nl y g o t o a 2. 5 c m 2 
( 0. 4 i nc h 2) ar ea of s ki n at eac h t u bi n g site.  T he a m o u nt t hat e nters t he s ki n is ver y s mall.  H o we ver, 
t here is a c h a nce of ha vi n g a ba d reacti o n t o t he s u bsta nces.  T his reacti o n c o ul d pr o d uce re d ness, 
itc hi n g, ras h, a n d/ or s welli n g.  A w orse reacti o n c o ul d als o ca use fe ver, breat hi n g pr o ble ms, c ha n ges i n 
p ulse, c o n v ulsi o ns, a n d/ or fai nti n g.  We a n d ot her researc hers ha ve us e d t hese s u bsta nces wit h 
micr o dial ysis i n s ki n.  T here ha v e bee n n o re p orts t hat t hese s u bsta nces ca use d ba d reacti o ns.  If a ba d 
reacti o n s h o ul d occ ur, w e s u m m o n me dical hel p. 
 
L act ate d Ri n ger’s S ol uti o n:   T his fl ui d is si milar t o t he nat ural fl ui ds i n y o ur s ki n. T his fl ui d c o ntai ns 
salt, p otassi u m, lactate, a n d c hl ori de.  T he aci d c o nte nt is li ke t hat i n y o ur b o d y’s nat ural fl ui ds.  A ba d 
reacti o n t o t his fl ui d is hi g hl y u nli kel y. 
  
Acet ylc h oli ne, A n gi ote nsi n II, L- N A M E, S N P:  T hese s u bsta nces st o p or mi mic t he acti o n of y o ur 
b o d y’s nat ural c h e micals u p o n t he bl o o d vessels i n t he s ki n.  A s mall a m o u nt of t hese s u bsta nces e nter 
t he s ki n ar o u n d t he t u bi n g.  T his o nl y affects t he bl o o d fl o w i n t he vessels i n t hat nic kel-size d area of 
s ki n.  T he eff ect of t hes e s u bsta nces i n y o ur s ki n is g o ne wit hi n a n h o ur aft er t he e x peri me nt.  
 
Acet ylc h oli ne  ( A C h) - ca uses bl o o d vessels t o dilate ( get wi der).  
A n gi ote nsi n II ( A n g II) - ca uses bl o o d vessels t o c o nstrict ( get s maller). 
L- N A M E – li ke a s u bsta nce ma de b y y o ur b o d y; pre ve nts s o me bl o o d vessel dilati o n. 
S o di u m Nitr o pr ussi de ( S N P) - ca us es bl o o d vessels t o dilate as m uc h as t he y ca n. 
 
L aser D o p pler Fl o w m et r y:   Wea k lasers ca n h urt y o ur e ye if y o u stare i nt o t he li g ht f or a l o n g ti me.  
We d o n ot t ur n o n t he las er u ntil t he pr o bes are ta p e d t o a s urface.  T h e ta pe ma y irritate y o ur s ki n. 
 
Bl o o d Press ure : T he r es earc h ers meas ure bl o o d press ure wit h t he met h o d use d i n a d oct or’s office a n d 
t he y ca n use a mac hi ne.  A c uff i nflat es o n t he u p per ar m.  As t h e c uff sl o wl y deflates, t he researc h ers 
liste n wit h a stet h osc o pe at t he be n d i n t he el b o w or t he mac hi ne ta k es a rea di n g.  D uri n g t he s h ort ti me 
t he researc h ers i nflate t h e c uff, y o ur ar m ma y feel n u m b or ti n gl y.  T he c uff c o ul d ca us e mil d br uisi n g. 
   
P o vi d o ne I o di ne:  Resear c hers a n d h os pitals use t his ora n ge-c ol ore d fl ui d t o clea n t he s ki n.  Y o u c o ul d 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 8 of 1 2  
ha ve a b a d reacti o n if y o u are aller gic t o i o di ne. Y o u nee d t o i nf or m us if y o u ha ve t his aller g y. I n t his 
case, w e use o nl y alc o h ol i nstea d.  A ba d reacti o n c o ul d ca use re d ness, itc hi n g, ras h, a n d/ or s w elli n g.  A 
w orse r eacti o n c o ul d als o ca use f e ver, breat hi n g pr o ble ms, c ha n ges i n p ulse, c o n v ulsi o ns, a n d/ or 
fai nti n g. 
 
Bl o o d Dr a w :  Bl o o d dra ws ofte n ca us e mil d pai n, br uisi n g, s welli n g, or blee di n g.  T here is als o a sli g ht 
c ha nce of i nfecti o n or a s mall cl ot.  If y o u are n er v o us a b o ut nee dles, bl o o d press ure a n d heart rate m a y 
i ncreas e f or a little w hile.  Y o u ma y als o feel li g ht hea de d, sic k t o y o ur st o mac h, or ma y fai nt.  Usi n g t he 
sa me tec h ni q ues use d i n h os pitals kee ps t he c ha n ce of i nfecti o n mi ni mal. 
 
T a pe a n d stic k y dis ks:    T he ta pe or stic k y dis ks c o ul d ca use a ras h.  D uri n g scree ni n g, y o u tell us if 
y o u are se nsiti ve t o ta pe.  If a dis k stic ks ver y str o n gl y, re m o vi n g t he dis k c o ul d ca use a n a brasi o n li ke a 
r u g- b ur n o n y o ur s ki n.  A n a brasi o n ca n feel te n der or sli g htl y pai nf ul, a n d ca n i ncrease ris k of i nfecti o n.  
If y o u ar e se nsiti ve t o ta p e, y o u ma y ha ve a n i ncrease d c ha n ce f or a brasi o n. If y o u get a n a brasi o n, 
a nti bi otic oi nt me nt a n d a sterile ba n da g e are a p plie d.  We tell y o u h o w t o ta ke care of t he site.  
 
Me dic al Scree ni n g:   Y o u ma y feel s h y a b o ut gi vi n g healt h i nf or mati o n.  T he staff c ollects t he 
i nf or mati o n i n a pri vate a n d pr ofessi o nal ma n ner.  Y o u ma y feel s h y a b o ut bei n g meas ure d.  Y o u ma y 
re q uest s o me o ne of t he s a me se x t o c o n d uct t he s cree ni n g. 
 
I niti al scree ni n g f or m:  O nl y me m bers of o ur la b gr o u p use t his f or m.  We use t he f or m t o hel p deci de 
w het her y o u are a g o o d ca n di date f or t h e st u d y. Y o u ma y feel s h y a b o ut a ns weri n g q uesti o ns.  Y o u ma y 
re q uest s o me o ne of t he s a me se x t o as k y o u t he q uesti o ns.  We c ollect t he i nf or mati o n i n a pri vate a n d 
pr ofessi o nal ma n ner.  We kee p t he c o m plete d f or m c o nfi de ntial a n d sec ure. 
 
E C G He art R at e:  T his mac hi ne meas ures t he el ectrical acti vit y of y o ur h eart.  Y o u ha v e 3 wires fr o m 
t he mac hi ne ta pe d t o s p ots o n y o ur c hest.  T here h a ve bee n n o a d verse effects.  T he ta pe ma y irritate. 
 
L oc al he ati n g:  We meas ure t he te m perat ure of y o ur s ki n u n der t he h ol ders.  D uri n g heati n g, t he s ki n 
feels ver y war m b ut will n ot h urt.  T he heati n g ma kes t he s ki n u n der t he h ol der re d li ke w h e n y o u ta ke a 
h ot bat h.  T he re d n ess g oes a wa y wit hi n se veral h o urs.  S o me pe o ple ma y be m ore se nsiti ve t o heati n g.  
If y o ur ar m feels t o o h ot, tell us, a n d we will re d u ce or st o p t he heati n g. 
 
S als al ate:   Salsalate is a n o n -ster oi dal a nti-i nfla m mat or y dr u g ( N S AI D).  It is part of a gr o u p of dr u gs 
calle d “salic yl ates.”  D o ct ors use t his dr u g t o treat pai n, s welli n g, a n d j oi nt stiff ness ca use d b y art hritis.   
Y o u will n ot be i n t he st u d y if y o u ha ve a k n o w n aller g y t o as piri n or N S AI D.  Y o u c o ul d ha ve a n 
aller g y t hat is u n k n o w n t o y o u.  A n aller gic reacti o n c o ul d i ncl u de hi ves, diffic ult breat hi n g, a n d 
s welli n g of y o ur face, li ps, t o n g ue, or t hr oat.  T here is a sli g ht ris k of i ncrease d c ha nce of blee di n g w hile 
o n t his dr u g ( < 0. 0 0 1 %).  If salsalate ca uses u ps et st o mac h, y o u ma y ta ke t h e dr u g wit h f o o d, mil k, or a n 
a ntaci d.  Please tell us if y o u ha ve a n y si de effects of t he me dicati o n i ncl u di n g t he f oll o wi n g si de effects.   
Less seri o us si de effects ma y i ncl u de:  
•  u pset st o mac h, heart b ur n; or 
• 
mil d dizzi ness.  
• 
ti n nit us 
Seri o us si de eff ects  – st o p ta ki n g t he dr u g a n d see k me dical hel p ri g ht a w a y if y o u ha ve a n y of t hes e 
•  c hest pai n, se vere dizzi ness, s h ort ness of breat h, sl urre d s peec h, pr o bl e ms wit h visi o n or bala nce; 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 9 of 1 2  
•  s u d de n n u m b ness or wea k ness, es peciall y o n o ne si de of t he b o d y; 
•  feeli n g li ke y o u mi g ht pass o ut; 
•  blac k, bl o o d y, or tarr y st o ols; 
•  c o u g hi n g u p bl o o d or v o mit t hat l o o ks li ke c offee gr o u n ds; 
•  heari n g pr o ble ms, ri n gi n g i n y o ur ears; 
•  s welli n g i n y o ur ha n ds or feet, r a pi d wei g ht gai n; 
•  fast or p o u n di n g heart beats; 
•  eas y br uisi n g or blee di n g, fe ver, c hills, s ore t hr oat, fl u s y m pt o ms; 
•  uri nati n g m ore or less t ha n us ual; 
•  se vere st o mac h pai n, o n g oi n g na usea or v o miti n g; or 
•  dar k uri ne, ja u n di ce ( y ell o wi n g of t he s ki n or e yes). 
 
L ate x:   S o me gl o ves a n d me dical materials are m a de of late x r u b ber.  Y o u will i nf or m us if y o u are 
aller gic t o late x a n d d ecli ne t o partici pate i n t he st u d y.  
 
T here is a ris k of l oss of c o nfi de ntialit y if y o ur i nf or mati o n or y o ur i de ntit y is o btai ne d b y s o me o ne 
ot her t ha n t he i n vesti gat ors, b ut preca uti o ns will b e ta ke n t o pre v e nt t his fr o m ha p pe ni n g.  T he 
c o nfi de ntialit y of y o ur el ectr o nic dat a cr eate d b y y o u or b y t he res earc hers will be mai ntai ne d t o t he 
de gree p er mitte d b y t he t ec h n ol o g y use d. A bs ol ut e c o nfi de ntialit y ca n n ot b e g uara nt ee d. 
 
W H A T A R E T H E B E N E FI T S O F T HI S S T U D Y ?  
We d o n’t k n o w if y o u will be nefit fr o m bei n g i n t his st u d y. 
 
H o we ver, we h o p e t hat, i n t he f ut ure, ot her p e o ple mi g ht be nefit fr o m t his st u d y beca use p reecla m psia 
affects ~ 5- 8 % of pre g n a n cies i n t he U nite d States, a n d ~ 8 milli o n pre g na nci es w orl d wi de.  W o m e n w h o 
get preecla m psia  ha ve 2 - 4 ti mes greater ris k f or d e vel o pi n g car di o v asc ular diseases  later i n life.  
Car di o vasc ular disease  is t he lea di n g ca us e of deat h a m o n g w o me n w orl d wi de. T he k n o wle d ge t o b e 
gai ne d i n t his st u d y is esse ntial t o u n dersta n di n g t he c o n necti o n bet wee n preecla m psia a n d 
car di o vas c ular disease .  T his k n o wle d ge c o ul d ai d t he de vel o p me nt of ne w met h o ds f or ma na gi n g t he 
ris ks i n t hese w o me n.   
 
WI L L I T C O S T M E A N Y T HI N G T O B E I N T HI S S T U D Y ?  
Y o u will n ot ha ve a n y c osts f or bei n g i n t his researc h st u d y. 
 
WI L L I B E P AI D F O R P A R TI CI P A TI N G ?  
Y o u will be pai d f or bei n g i n t his researc h st u d y   Y o u ma y als o nee d t o pr o vi de y o ur a d dress if a c hec k 
will be maile d t o y o u.     
 
E x peri m e nt al visits: $ 7 5 per visit ( $ 1 5/ micr o dial ysis pr o be + $ 7. 5 0/ h o ur) 
T ot al f or c o m pleti n g t he st u d y: $ 1 5 0 (t w o c o m plete d st u d y visits) 
Y o u will be gi ve n a par ki n g pass f or ti me i n v ol ve d at st u d y a n d scree ni n g visits.  
  
Pr o -r ati n g: Y o u ca n recei ve pa y me nt f or e x peri me nts n ot c o m plete d.  T he researc h ers pa y a n a m o u nt 
of m o ne y e q ual t o t he part c o m plete d.  F or i nsta nce, if y o u c o m plete h alf of E x peri me nt 1, y o u recei ve 
$ 1 5. 0 0 f or eac h pr o b e i nserte d pl us $ 7. 5 0 f or eac h h o ur c o m plete d. If y o u are as ke d t o re peat a trial a n d  
a gree t o re peat a trial, y o u will recei ve p a y me nt f or t he re p eate d trial as state d a b o ve. 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 1 0  of 1 2  
 
W H O I S F U N DI N G T HI S S T U D Y ?  
T he Nati o nal Heart , L u n g , a n d Bl o o d I nstit ute ( N H L BI) of t he N ati o nal I nstit utes of Healt h  is f u n di n g 
t his resear c h st u d y.  T his mea ns t hat t he U ni versit y of I o wa is recei vi n g pa y me nts fr o m N H L BI t o 
s u p p ort t he acti vities t hat are r e q uire d t o c o n d u ct t he st u d y.  N o o ne o n t he researc h tea m will recei v e a 
direct pa y me nt or i n creas e i n salar y fr o m N H L BI f or c o n d ucti n g t his st u d y. 
 
W H A T I F I A M I N J U R E D A S A R E S U L T O F T HI S S T U D Y ?  
•  If y o u ar e i nj ure d or b ec o me ill fr o m ta ki n g part i n t his st u d y, me dical treat me nt is a vaila ble at t he 
U ni versit y of I o wa H os pitals a n d Cli nics. 
•  T he U ni versit y of I o wa d oes n ot pla n t o pr o vi de free me dical care or pa y m e nt f or treat me nt of a n y 
ill ness or i nj ur y res ulti n g fr o m t his st u d y u nless it is t he direct res ul t of pr o ve n ne gli ge nce b y a 
U ni versit y e m pl o yee.   
•  If y o u e x perie nce a r esearc h-r elate d ill ness or i nj ur y, y o u a n d/ or y o ur me di cal or h os pital i ns ura nce 
carri er will be r es p o nsi ble f or t he c ost of treat me nt.  
 
W H A T A B O U T C O N FI D E N TI A LI T Y ?  
We will kee p y o ur p artici pati o n i n t his researc h st u d y c o nfi de ntial t o t he e xt e nt per mitte d b y la w.  
H o we ver, it is p ossi ble t hat ot her pe o ple s u c h as t h ose i n dicate d bel o w ma y bec o me a ware of y o ur 
partici pati o n i n t his st u d y  a n d ma y i ns pect a n d c o p y rec or ds p ertai ni n g t o t his researc h.  S o me of t hes e 
rec or ds c o ul d c o ntai n i nf or mati o n t hat pers o nall y i de ntifies y o u.  
•  fe der al g o ver n me nt re g ul at or y a ge n cies,  
•  U. S. F o o d a n d Dr u g A d mi nistrati o n  
•  a u diti n g de part me nts of t he U ni versit y of I o w a, a n d  
•  t he U ni versit y of I o w a I nstit uti o nal Re vie w B oar d (a c o m mittee t hat re vi e ws a n d a p pr o ves 
researc h st u dies)  
  
T o hel p pr otect y o ur c o nfi de ntialit y, we will li mit t he use a n d s hari n g of y o ur pers o nal researc h 
i nf or mati o n t o pe o ple w h o ha ve a n ee d t o re vi e w t his i nf or mati o n. We kee p t he list t hat matc hes y o ur 
na me wit h y o ur c o de n u m ber i n a l oc ke d file or p ass w or d pr otecte d file o n a c o m p uter i n a r o o m t hat is 
l oc ke d w he n u n o cc u pie d.  O nl y a ut h orize d me m bers of t he la b ha v e access t o t he list. We la bel y o ur 
researc h r ec or ds wit h y o ur c o de n u m ber a n d kee p t he m i n a l oc ke d file or pass w or d pr otecte d c o m p uter 
i n a r o o m t hat is l oc ke d w he n u n occ u pi e d. We l a bel y o ur researc h sa m ples wit h y o ur c o de n u m ber o nl y.  
If we write a r e p ort or article a b o ut t his st u d y or s hare t he st u d y dat a set wit h ot hers, we will d o s o i n 
s uc h a wa y t h at y o u ca n n ot be directl y i de ntifie d. 
 
T he U ni versit y of I o wa H os pitals a n d Cli nics ge nerall y re q uires t hat we d oc u me nt y o ur partici p ati o n i n 
researc h occ urri n g i n a U ni versit y of I o wa H ealt h Care facilit y.  T his d oc u me ntati o n will be i n eit her 
y o ur me dical r ec or d or a data base mai ntai n e d o n b e half of t he i nstit uti o n reflecti n g t hat y o u are 
partici pati n g i n t his st u d y. T he i nf or mati o n i ncl u de d will pr o vi de c o ntact i nf or mati o n f or t he researc h 
tea m as well as i nf or mati o n a b o ut t he ris ks ass ociate d wit h t his st u d y. We will kee p t his I nf or me d 
C o nse nt D oc u me nt i n o ur researc h files; it will n ot be place d i n y o ur me di cal rec or d c hart. 
 
WI L L M Y H E A L T H I N F O R M A TI O N B E U S E D D U RI N G T HI S S T U D Y ?  
 
T he Fe d er al Healt h I ns ur a nce P orta bilit y a n d Acc o u nta bilit y Act ( HI P A A) re q uires U ni v ersit y of I o wa 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 1 1  of 1 2  
Healt h Care  t o o btai n y o ur per missi o n f or t he researc h tea m t o access or create “ pr otecte d h ealt h 
i nf or mati o n” a b o ut y o u f or p ur p oses of t his res earc h st u d y.  Pr otecte d healt h i nf or mati o n is i nf or mati o n 
t hat pers o nall y i de ntifies y o u a n d relates t o y o ur p ast, prese nt, or f ut ure p h ysical or me ntal healt h 
c o n diti o n or car e.  We  will access or create healt h i nf or mati o n a b o ut y o u, as descri be d i n t his d oc u m e nt, 
f or p ur p oses of t his r esearc h st u d y.  O nce U ni versit y of I o w a Healt h Care h as discl ose d y o ur pr otecte d 
healt h i nf or mati o n t o us, it ma y n o l o n ger be pr otecte d b y t he Fe deral HI P A A  pri vac y re g ulati o ns, b ut 
we will c o nti n ue t o pr otect y o ur c o nfi de ntialit y as descri be d u n d er “ C o nfi d e ntialit y.” 
 
We  ma y s hare y o ur h ealt h i nf or mati o n relate d t o t his st u d y wit h ot her parties i ncl u di n g fe deral 
g o ver n me nt re g ul at or y a ge nci es, t he U ni versit y of I o wa I nstit uti o nal Re vie w B oar ds a n d s u p p ort staff, 
t he Nati o nal I nstit utes of Healt h, a n d t he U. S. F o o d a n d Dr u g A d mi nistrati o n.   
 
Y o u ca n n ot partici pate i n t his st u d y u nless y o u per mit us t o use y o ur pr otecte d  healt h i nf or mati o n.  If 
y o u c h o ose n ot  t o all o w us t o use y o ur pr otecte d healt h i nf or mati o n, we will disc uss a n y n o n-researc h 
alter nati ves a v aila ble t o y o u.  Y o ur decisi o n will n ot affect y o ur ri g ht t o me dical care t hat is n ot 
researc h-relate d.  Y o ur si g nat ure o n t his C o nse nt D oc u me nt a ut h orizes U ni versit y of I o wa H ealt h Care  
t o gi ve us per missi o n t o use or cr eate h ealt h i nf or mati o n a b o ut y o u. 
 
Alt h o u g h y o u ma y n ot be all o we d t o see st u d y i nf or mati o n u ntil after t his st u d y is o ver, y o u ma y be 
gi ve n access t o y o ur healt h care rec or ds b y c o ntacti n g y o ur healt h care pr o vi der. Y o ur per missi o n f or us 
t o access or cr eate pr ot ecte d healt h i nf or mati o n a b o ut y o u f or p ur p oses of t his st u d y has n o e x pirati o n 
date. Y o u ma y wit h dra w y o ur per missi o n f or us t o use y o ur healt h i nf or m ati o n f or t his researc h st u d y b y 
se n di n g a writte n n otice t o: A n na Sta n he wicz, 4 1 0 Fiel d H o use, 2 2 5 S o ut h Gra n d A v e n ue, I o w a Cit y, I A 
5 2 2 4 2. H o we ver, we  ma y still use y o ur healt h i nf or mati o n t hat was c ollect e d bef ore wit h dra wi n g y o ur 
per missi o n.  Als o, if we ha ve  se nt y o ur h ealt h i nf or mati o n t o a t hir d part y, s uc h as t he st u d y s p o ns or, or 
we ha ve  re m o ve d y o ur i de ntif yi n g i nf or mati o n, it ma y n ot be p ossi ble t o pre ve nt its f ut ure use.  Y o u will 
recei v e a c o p y of t his si g ne d d oc u me nt. 
 
I S B EI N G I N T HI S S T U D Y V O L U N T A R Y ? 
Ta ki n g part i n t his resear c h st u d y is c o m pletel y v ol u ntar y.  Y o u ma y c h o os e n ot t o ta ke part at all.  If 
y o u deci de t o be i n t his st u d y, y o u ma y st o p partici pati n g at a n y ti me.  If y o u deci de n ot t o be i n t his 
st u d y, or if y o u st o p partici pati n g at a n y ti me, y o u w o n’t be pe nalize d or l os e a n y be n efits f or w hic h y o u 
ot her wise q ualif y.  
 
Will I Recei ve Ne w I nf o r m ati o n A b o ut t he St u d y w hile P artici p ati n g ?  
If we o btai n a n y ne w i nf or mati o n d uri n g t his st u d y t hat mi g ht affect y o ur willi n g ness t o c o nti n ue 
partici pati n g i n t he st u d y, we’ll pr o m ptl y pr o vi de y o u wit h t hat i nf or mati o n. 
 
C a n S o m e o ne Else E n d m y P artici p ati o n i n t his St u d y ?  
U n der certai n cir c u msta n ces, t he r esearc hers mi g ht deci de t o e n d y o ur p arti ci pati o n i n t his researc h 
st u d y earlier t ha n pla n n e d.  T his mi g ht ha p pe n if y o u bec o me pre g na nt, if t he researc h er deci des t o e n d 
t he st u d y earl y, or if f or a n y reas o n t he researc h er deci des t hat it is n o l o n ger safe f or y o u t o c o nti n ue.  
 
W H A T I F I H A V E Q U E S TI O N S ?  
We e n c o ura g e y o u t o as k q uesti o ns.  If y o u h a ve a n y q uesti o ns a b o ut t he researc h st u d y itself, please 
c o ntact: A n na Sta n he wicz ( 3 1 9) 4 6 7- 1 7 3 2. If y o u e x perie n ce a researc h-relate d i nj ur y, please c o ntact: 


F O R I R B U S E O N L Y  
A P P R O V E D B Y: I R B -0 1  
I R B I D #: 2 0 1 9 0 9 8 1 8 
A P P R O V A L D A T E: 0 9/ 2 4/ 2 0  
 
 
 
P a ge 1 2  of 1 2  
A n na Sta n he wicz ( 3 1 9) 4 6 7- 1 7 3 9.  
 
If y o u ha ve q u esti o ns, c o ncer ns, or c o m plai nts a b o ut  y o ur ri g hts as a res earc h s u bject or a b o ut researc h 
relate d i nj ur y, please c o ntact t he H u ma n S u bjects Office, 1 0 5 Har di n Li brar y f or t he H ealt h Scie nces, 
6 0 0 Ne wt o n R d, T he U ni versit y of I o wa, I o wa Cit y, I A  5 2 2 4 2- 1 0 9 8, ( 3 1 9) 3 3 5- 6 5 6 4, or e- m ail 
ir b @ ui o wa.e d u.  G e ner al i nf or mati o n a b o ut bei n g a researc h s u bj ect ca n be f o u n d b y clic ki n g “I nf o f or 
P u blic” o n t he H u ma n S u bjects Office we b site, htt p:// hs o.researc h. ui o w a.e d u/ . T o offer i n p ut a b o ut 
y o ur e x peri e nces as a r es earc h s u bj ect or t o s pea k t o s o me o ne ot her t ha n t h e researc h st aff, call t he 
H u ma n S u bjects Office at t he n u m ber a b o ve. 
 
 
T his I nf or me d C o nse nt D oc u me nt is n ot a c o ntract. It is a writte n e x pla n ati o n of w hat will ha p pe n 
d uri n g t he st u d y if y o u deci de t o partici p ate. Y o u are n ot wai vi n g a n y l e gal ri g hts b y si g ni n g t his 
I nf or me d C o nse nt D o c u me nt. Y o ur si g nat ure i n dicates t hat t his researc h st u d y has bee n e x plai ne d t o 
y o u, t hat y o ur q uesti o ns ha ve bee n a ns were d, a n d t hat y o u a gree t o ta k e part i n t his st u d y.  Y o u will 
recei v e a c o p y of t his f or m. 
 
 
S u bject's Na me ( pri nte d):  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
( Si g nat ure of S u bject)   
  
  
  
 
( Date) 
 
St ate m e nt of Pers o n W h o O bt ai ne d C o nse nt  
 
I h a ve disc usse d t h e a b o v e p oi nts wit h t he s u bject or, w here a p pr o priate, wit h t he s u bject’s le gall y 
a ut h orize d r e pres e ntati ve.  It is m y o pi ni o n t hat t he s u bject u n dersta n ds t h e ris ks, be nefits, a n d 
pr oce d ur es i n v ol ve d wit h partici pati o n i n t his researc h st u d y. 
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
( Si g nat ure of Pers o n w h o O btai ne d C o nse nt)  
 
( Date)